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ABSTRACT 
 
REBECCA LYNN SAYERS:  Focal Adhesion Kinase and its Endogenous Inhibitor, 
FRNK, in Vascular Development and Injury 
(Under the direction of Joan M. Taylor, Ph.D.) 
 
 
  Development and maintenance of a circulatory system is required for transport of 
essential gases and nutrients in vertebrates.  Within this work, I have aimed to elucidate 
the role of a certain family of adhesion signaling molecules in regulating the responses of 
vascular smooth muscle cells (VSMC) that enable circulatory vessels to form and 
maintain a differentiated phenotype.  Focal adhesion kinase (FAK) is a non-receptor 
tyrosine kinase that coordinates signaling from integrins, growth factor receptors, and G-
protein coupled receptors.  While FAK is ubiquitously expressed, its variant FAK-related 
non kinase (FRNK) is selectively expressed in smooth muscle containing tissues.  Our 
group has recently demonstrated that over-expression of FRNK in vascular smooth 
muscle cells (VSMC) can attenuate PDGF-stimulated proliferation and migration of 
vascular smooth muscle cells.  FRNK is highly expressed during early postnatal 
development (particularly in large arteries) and two weeks following endovascular injury 
in the rat femoral artery.  Regulation of FRNK in smooth muscles cells is unique in that 
FRNK is expressed as a gene within a gene under the control of non-coding sequence 
within a FAK intron.  This FRNK promoter sequence is void of CArG boxes, making 
transcription independent of serum response factor (SRF).  Germline deletion of FAK 
causes mesodermal defects resulting in embryonic lethality, implicating FAK as a 
significant regulator of vascular development.  Since FAK-/- embryos die prior to 
complete formation of the vasculature, we used a conditional approach to delete FAK 
specifically in cardiac neural-crest derived cells.  The goals of this work were to (1) 
determine the factors that regulate SRF-independent smooth muscle-specific expression 
of FRNK, (2) use a gene ablation model to elucidate an in vivo function for FRNK, and 
(3) use SMC-specific conditional knockout approach to examine a role for FAK in 
vascular development.  Herein we found that FRNK expression is regulated by TGF- 
and extracellular matrix components.  Conservation analysis revealed two ~100-150 bp 
regions of the FRNK promoter that are over 75% conserved between mouse, rat and 
human.  Although we found that FRNK-/- mice exhibit increased phosphorylation of 
FAKY397 and proliferation our most striking observation was that deletion of FRNK 
causes decreased expression of smooth muscle -actin, smooth muscle myosin heavy 
chain, and smoothelin during postnatal development and in the neointima following 
carotid artery ligation.  Likewise, overexpression of FRNK stimulated smooth muscle 
promoter activity in serum and enhanced TGF- mediated increases in smooth muscle 
promoter activity.  To study the role of FAK in development of cardiac neural crest-
derived smooth muscle cells, we used a previously described Wnt-1-Cre expressing 
mouse to conditionally delete FAK in this cell population.  We found that deletion of 
FAK resulted in malformation of the aorticopulmonary septum and that animals did not 
survive to adulthood.  Additional in vivo and in vitro studies revealed that FAK activity 
downregulates activity of smooth muscle specific genes.  The studies described herein 
indicate that the adhesion signaling molecule FAK and its truncated family member, 
FRNK, regulate smooth muscle cell phenotype. 
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INTRODUCTION
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INTRODUCTION 
 
 Proper development and maintenance of the cardiovascular system is essential for 
survival.  The circuitry of vessels contained within the human body is responsible for 
transporting essential gases and nutrients to all cells in the body.  This work addresses the 
specific role of smooth muscle cells in development of the vasculature, maintenance of 
mature vessels, and response to vascular injury.  More specifically, this work aims to 
elucidate a role for adhesion signaling proteins in regulation of certain vascular smooth 
muscle cell processes such as proliferation, migration, and differentiation.  This chapter 
reviews smooth muscle cell biology and smooth muscle cell signaling through focal 
adhesion kinase (FAK) and its variant FAK-related non-kinase, or FRNK. 
 
BIOLOGY OF SMOOTH MUSCLE CELLS 
The Developing Vasculature 
 
 During mammalian development, the generation of a closed circulatory system is 
essential for the successful maturation of the embryo.  Even during early stages of 
embryogenesis, prior to commencement of high rates of blood flow, a complete network 
of vessels must be formed to provide nourishment to the embryo.  Indeed, numerous 
animal studies demonstrate that genetic disruptions causing defective development of the 
embryonic or extra-embryonic vasculature result in embryonic lethality. 
 Early in development, endothelial cells derived from the mesenchyme of the 
embryo begin to align and form a network of tubes.  One of the first vascular tubes to 
form includes cells that will line the dorsal aorta of the animal (1).  During angiogenesis, 
additional vessels sprout from endothelial tubes to begin formation of a vascular plexus.  
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Eventually, pericytes derived from nearby progenitors within the surrounding 
mesenchyme, epicardium, or neural crest cell populations are recruited to sites of 
endothelial tube formation (see below) (2).  The initial investment of smooth muscle cells 
begins forming the contractile muscle layer for the vessel.  PDGF-BB (platelet-derived 
growth factor-BB) and VEGF (vascular endothelial growth factor) signaling leads to 
further recruitment and proliferation of smooth muscle cells concomitant with increased 
expression of contractile proteins such as SM -actin and SM-myosin heavy chain (2).  
In addition, smooth muscle cells secrete extracellular matrix proteins, including those that 
will comprise the elastic laminae. 
 
Origin and Heterogeneity of Smooth Muscle Cells 
 
 The developmental origin of vascular smooth muscle cells has been a subject of 
close study.  It is difficult to pinpoint when and where the initial steps of smooth muscle 
cell differentiation begin, since markers for smooth muscle cells are not entirely specific.  
Evidence has shown that smooth muscle cells, even those within the same vessel, can 
come from different populations of progenitor cells, contributing to heterogeneity.  
Vascular smooth muscle cells have been shown to arise from several different lineages 
including neural crest, secondary heart field, proepicardium, somites, mesangioblasts, 
mesothelium, and splanchnic mesoderm (3).  For example, smooth muscle cells of the 
coronary arteries are derived from proepicardial cells (4) while neural crest-derived cells 
form smooth muscle cells of the cardiac outflow tract, as discussed in greater detail 
below.  This diversity bears pathological relevance, since vessels arising from distinct 
lineages have different responses to identical vascular injury.  In addition, smooth muscle 
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contractile gene expression appears to be regulated differently in various smooth muscle 
populations (reviewed by Majesky (3)). 
 Although smooth muscle cell heterogeneity is attributed in large part to 
differences in lineage, it is also greatly impacted by the vessel microenvironment.  Each 
vessel, independent of origin, exists in a unique environment, causing smooth muscle 
cells to respond to extrinsic biological cues in different ways.  For example, the specific 
hemodynamics of a particular vessel affect the ability of smooth muscle cells in that 
vessel to respond to autocrine or paracrine agents, as differing rates of flow may affect 
the length of time the vessels are exposed to humoral agents (reviewed by Berk (5)).  In 
addition to the rate of flow, smooth muscle cell behavior is also dependent on the type of 
flow present in the environment.  Vascular flow is generally laminar, with the fastest 
blood velocity in the middle of the vessel and the slowest against the vessel wall.  
However, at points of bifurcation, flow becomes disorganized, and is referred to as 
turbulent.  Vessels exposed to turbulent flow are at higher risk for development of 
atherosclerotic lesions, as discussed later.  In addition, the extracellular matrix 
composition of a particular vessel is important in smooth muscle response to injury.  
Finally, the presence of specific matrix components, such as fibronectin or laminin, can 
alter the reactivity of smooth muscle cells to certain proliferative agonists (6-8).  The 
combined diversity of cell origin and environment complicates the study of smooth 
muscle cells, but must be considered when studying the function of smooth muscle cells 
in different developmental and pathological paradigms. 
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Formation of the Cardiac Outflow Tract 
 
 A specific example of vascular development relevant to this work is formation of 
the cardiac outflow tract from cardiac neural crest-derived cells.  Cardiac neural crest 
cells arise from the dorsal neural tube, and are named such not because they only form 
cardiac tissue, but because ablation of these cells causes cardiac abnormalities (9).  Cells 
derived from this population contribute to parasympathetic nerves of the heart, thymus, 
thyroid, parathyroid, and most notably for this discussion, smooth muscle cells of the 
cardiac outflow tract and aorticopulmonary septum (10-12).  Migration of these cells 
from the neural crest to the circumpharyngeal ridge is dependent on expression of the 
family of Wnt proteins (13).  At this site, cardiac neural crest cells are involved in the 
formation of pharyngeal arches 3, 4, and 6, which eventually form vasculature and glands 
(9).  Cardiac neural crest cells proliferate and migrate to follow mesenchymal cells into 
the cardiac outflow cushions (14).  Migration of these cells is the first step required for 
formation of the aorticopulmonary septum, followed by differentiation of cells into 
smooth muscle and myocardium and fusion of the cushions (9).  Cells within the outflow 
tract differentiate into smooth muscle cells, and gene ablation mouse models have 
indicated that differentiation of smooth muscle cells is required for proper development 
of the outflow tract.  For example, deletion of ALK2 in Wnt1-expressing cells leads to 
impaired cardiac neural crest migration and expression of smooth muscle genes around 
the aortic arch (15).  Additionally, knockout of MRTF-B, a myocardin-family member 
discussed below, results in embryonic lethality due to malformation of the aortic arch 
(16, 17).  Since the ability of cardiac neural crest cells to migrate and differentiate into 
smooth muscle cells is essential for correct development of the outflow tract, further 
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characterization of the molecules necessary for proliferation, migration, and 
differentiation must be pursued. 
 
Smooth Muscle Cells in the Mature Vascular Wall 
 
After complete development of the vasculature, the walls of large vessels contain 
three distinct layers that each carry out a specialized supportive function.  The innermost 
layer, or tunica intima, is a single layer of endothelial cells lining the lumen of the vessel.  
This layer acts as a selective barrier for the vessel and transmits information from the 
bloodstream to surrounding cells.  Smooth muscle cells form the tunica media and 
respond to signals from endothelial cells, circulating peptides, and direct nerve 
stimulation to regulate vascular tone and resistance and maintain mean arterial pressure 
(5).  The outermost layer, the tunica adventitia, consists mainly of adventitial fibroblasts 
and other connective tissue that supports the vessel.   
 In a mature vessel, smooth muscle cells within the tunica media have a contractile 
phenotype and express receptors for a variety of vasoactive stimuli, including 
catecholamines, prostaglandins, peptides, and steroid hormones.  However, unlike 
striated muscle, smooth muscle cells maintain plasticity following development and can 
dedifferentiate from their contractile phenotype to a proliferative phenotype.  During 
disease states or following injury, a complement of growth factors and extracellular 
matrix initiates expression of pro-proliferative genes, which in turn triggers a gene 
expression profile similar to that seen during development.  These gene expression 
changes lead to proliferation of smooth muscle cells through activation of growth factor 
receptors and integrins, which is an important factor in response to vascular injury (5). 
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Smooth Muscle Cells in Vascular Disease 
 
Hypertension: 
 In 2005, nearly one third of the United States population over age suffered from 
hypertension (18).  Smooth muscle cell growth is thought to contribute to the 
development of this disease.  Changes in pressure within the vessel wall cause the vessel 
to remodel; in the case of hypertension, the smooth muscle-containing tunica media 
thickens.  Studies have demonstrated chronic hypertension is accompanied by an increase 
in wall thickness that compensates for additional stress on the vessel (19, 20).  
Hyperplasia, an increase in cell number, and hypertrophy, an increase in cell size, are two 
growth mechanisms known to increase medial thickness.  Normally, differentiated 
smooth muscle cells within the vascular wall exhibit a very low proliferation rate.  In 
normotensive rats, smooth muscle cells proliferate at a rate of 0.1% per day, but 
spontaneously hypertensive rats (SHR) exhibit hyperplasia with a rate increase to 1% per 
day (21).  In chronic hypertension, there can be hypertrophy with or without an increase 
in DNA.  A well-studied mechanism of hypertension is an increase in cell volume due to 
increased retention of water within the cell.  This is generally true in cases of salt-
sensitive hypertension, and can usually be reversed.  However, hypertrophy with an 
increase in DNA content is generally irreversible (22, 23).  Owens, et al. previously 
showed that in comparison to normotensive controls, SHR have an increase in DNA/cell 
ratio and an increase in the number of polyploid smooth muscle cells (24).  Hyperplasia 
and hypertrophy can be mediated by autocrine and paracrine growth factors such as 
PDGF-A and IGF-1, both of which are elevated during hypertension (25-27).   
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Atheroclerosis:  
According to the American Heart Association, 13.9 million Americans suffered 
from a heart attack or stroke in 2005, and the development of atherosclerosis is a major 
contributor to this statistic.  There are many factors that put humans at risk for 
atherosclerosis, including elevated cholesterol, hypertension, diabetes, and smoking.  
Atherosclerosis is defined as a narrowing of a vessel due to the formation of a plaque, or 
atheroma, consisting of fatty cholesterol deposits.  The resulting reduction in lumen 
diameter increases the risk for heart attack and stroke.  Understanding the mechanisms 
that contribute to atherosclerosis is critical for preventing the poor medical outcomes 
associated with this condition.   
In the development of the atherosclerotic plaque, deposition of fatty acids on the 
vessel wall results in the growth of large lesions which limit blood flow to vital organs.  
After initial lesion formation, smooth muscle cells, foam cells, macrophages, and 
lymphocytes migrate into the lesion and proliferate often leading to the formation of a 
large plaque.  There are many factors promoting formation of plaques, and several 
proposed mechanisms involve proliferation of smooth muscle cells (reviewed by Fitridge 
and Thompson (28)).  For example, it is well known that incidence of atherosclerosis is 
directly correlated with levels of low-density lipoprotein (LDL), which induces smooth 
muscle cell growth (29).  In addition, studies indicate that sites of disturbed flow within 
the vessel, such as areas of bifurcations, are at higher risk for lesion formation, possibly 
due to the ability of mechanical stress to induce smooth muscle cell proliferation (30).  In 
cultured cells, disturbed flow can also enhance signaling through the PDGF receptor, a 
potent and positive regulator of smooth muscle cell proliferation and migration (31).  As 
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mentioned previously, hypertension is a risk factor for development of atherosclerosis, 
possibly by increasing mechanical stress on the vascular wall causing smooth muscle 
cells to migrate, proliferate, and increase the rate of matrix deposition, contributing to 
plaque formation (32).  The studies mentioned here as well as numerous others have 
underscored the role that smooth muscle cells play in the development of atherosclerosis. 
Restenosis Post-Angioplasty: 
As detailed above, development of atherosclerosis causes a narrowing of the 
arterial lumen, resulting in decreased blood flow to organs.  This is of particular concern 
when blood flow to the heart or brain is compromised, as this can lead to heart attack and 
stroke.  Surgical intervention utilizes balloon angioplasty or stent implantation to 
mechanically remove blockage within the narrowed artery.  Although this increases 
lumen diameter and improves blood flow to the heart, either of these devices can cause 
injury to the vessel wall thereby inducing proliferation of smooth muscle cells within the 
medial layer.  This is followed by robust migration of smooth muscle cells into the 
lumen, forming a neointima.  Prior to recent therapeutic advances, 20% of patients who 
underwent surgery experienced re-growth of cells into the lumen and formation of a 
neointima (28).  This re-growth is clinically referred to as restenosis.  This is a significant 
problem, since further treatment after restenosis is more costly and puts the patient at 
higher risk repeat angioplasty or bypass surgery (28).   
The formation of the neointima is a multi-step process.    Injury to the 
endothelium triggers platelet deposition, resulting in the release of PDGF, a strong 
mitogen and chemoattractant for smooth muscle cells (33).   This is likely responsible for 
the subsequent increase in the proliferation rate of smooth muscle cells, rising from less 
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than 1% prior to injury to 10-40% following the injury (34-36).  These agonists first 
induce smooth muscle cells to defifferntiate and proliferate, and then undergo migration 
outside of the media.  After migration, smooth muscle cells again proliferate, thus 
obstructing the aterial lumen.  The neointima, newly populated with smooth muscle cells, 
is also subject to increased extracellular matrix deposition, resulting in a decline in 
smooth muscle proliferation.  Since smooth muscle cell growth, migration, and response 
to extracellular matrix are integral processes in neointima formation, it is of clinical 
importance to understand the adhesion- and growth factor-mediated signaling events 
behind restenosis. 
 
 
Regulation of Smooth Muscle Specific Gene Expression 
  
 As discussed previously, in response to injury smooth muscle cells retain the 
ability to return to a proliferative state following differentiation.  This phenotypic 
switching generally manifests as changes in proliferation and expression of smooth 
muscle marker genes such as SM -actin, SM-22, and SM-myosin heavy chain.  During 
development, it is the expression of these genes that first classifies a cell as smooth 
muscle.  SM -actin is the earliest known marker for smooth muscle cells, although 
during early embryogenesis and cardiac hypertrophy, its expression is not limited to 
smooth muscle cells (37).  SM-22 and SM-myosin heavy chain are more specific markers 
for smooth muscle cells, but expression is detected later in development.  SM-22 appears 
in smooth muscle cells at E9.5 (38).  Expression of SM-22 is also observed transiently in 
other muscle tissues such as the heart between E9.5 and 12.5 (38).  SM-myosin heavy 
chain is reported to turn on in the developing mouse aorta around E10.5 and in the arch of 
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the aorta and outflow tract vessels around E12.5 (39).  Expression of all three of these 
genes continues past development and remains high in mature, contractile smooth muscle 
cells.  Following a vascular injury such as angioplasty or stent implantation, expression 
of smooth muscle marker genes decreases as smooth muscle cells revert to a proliferative 
phenotype.  In a mouse model of guide wire-mediated injury to the carotid artery, 
expression of SM -actin and SM-myosin heavy chain decreased as early as 4 days 
following injury and returned to nearly normal levels 14 days following injury (40, 41).  
Since the expression of smooth muscle genes appears to be intricately regulated during 
both development and disease, much attention has been paid to the mechanisms that 
regulate these genes. 
 Expression of most smooth muscle specific genes is dependent on the presence of 
one or more CArG elements within the promoter (38, 42-47).  Mutation of any of the 
three CArG elements present within the smooth muscle -actin promoter was shown to 
ablate expression in a transgenic LacZ reporter mouse (43).  This is also true of mutations 
made to CArG elements within the SM-22, SM-MHC, and desmin promoters (42, 44, 
45, 48).  Serum response factor (SRF), a MADS box transcription factor, binds CArG 
elements to regulate transcription.  It is thought that SRF dimerizes upon binding to the 
CArG element (49).  Although the CArG element is necessary for smooth muscle specific 
expression of these genes, it is likely that a number of DNA response elements are 
required for combinatorial control of gene expression since SRF is ubiquitously 
expressed (47).  Smooth muscle-specific SRF-dependent gene expression is regulated by 
binding of coactivators to SRF, including myocardin and mycoardin-related transcription 
factor-A (MRTF-A).  It is also interesting to note that even though CArG-dependent gene 
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expression is the best described mechanism of smooth muscle differentiation, recent work 
has shown that myocardin is necessary, but insufficient for complete differentiation of 
smooth muscle cells (50).  Various growth factors have been identified as stimulators of 
smooth muscle gene expression, one significant example is TGF-, which is discussed 
below in detail. 
 
TGF- in the Vasculature 
 
 TGF- is important in both vascular development and disease.  Numerous studies 
have indicated that alteration of the TGF- signaling pathway leads to vascular defects 
during development resulting in embryonic lethality.  Mutation of the Type II TGF- 
receptor subtype leads to vascular malformations in developing mouse embryos (51, 52) 
and the Type I TGF- receptor is required for arterio-venous differentiation (53).  
Maintenance of TGF- levels during development also appears to be critical since both 
TGF- knockout mice and mice that overexpress TGF- under the control of a smooth 
muscle specific promoter have abnormalities in yolk sac vasculogenesis (54, 55).  In 
cultures of both primary smooth muscle cells and 10T1/2 cells (smooth muscle precursor 
cell line), TGF- increases expression of smooth muscle -actin and SM-22 (56, 57).  
Monc-1 cells (a neural crest cell line), can also be differentiated into contractile cells 
expressing smooth muscle markers by treatment with TGF-(58).  It has also been 
suggested that TGF- may facilitate recruitment and maintenance of smooth muscle cells 
by controlling media thickness (59).  Finally, transcription of TGF- mRNA increases 
following endovascular injury, and neutralizing antibodies directed towards TGF- block 
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the progression of neointimal formation, underscoring the pathological significance of 
this agent (60, 61). 
 TGF- stimulates transcription of responsive genes first by binding its own 
receptors (Type I and Type II) on the cell surface (62).  Binding of TGF- to its Type II 
receptor stimulates phosphorylation of the Type I receptor (62).  Receptor 
phosphorylation is followed by recruitment of Smad proteins to the receptor.  The Smad 
family of proteins has eight members, Smad1 through Smad8.  The Smads are 
categorized into three groups: receptor Smads, inhibitory Smads, and Co-Smads (63).  
Receptor Smads (Smads 1,2,3,5) are phosphorylated by the Type I receptor, and can 
subsequently bind a Co-Smad (Smad 4) in the cytoplasm (64).  Inhibitory Smads (Smads 
6 and 7) act as dominant negatives and prevent binding of R-Smads and Co-Smads (62).  
Active Smad complexes translocate to the nucleus and bind DNA response elements to 
enhance transcription of specific gene products (62).  Regulation of transcription can be 
either positive or negative, as Smad complexes can bind both co-repressors or co-
activators in the nucleus (63). 
  
SIGNALING THROUGH INTEGRINS AND FOCAL ADHESION KINASE IN VASCULAR 
SMOOTH MUSCLE CELLS 
 
Signaling Through Integrins  
 
Communication between a cell and its outside environment is a critical element of 
proper patterning during vessel development.  Integrins, the receptors for extracellular 
matrix (ECM) proteins, are important for both inside-out and outside-in signaling, in that 
they both regulate a cell’s response to the ECM and they can influence the 
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polymerization state of the matrix.  Integrins are transmembrane proteins forming 
heterodimers from a variety of  and  subunits.  Several integrin subtypes are enriched 
in vascular smooth muscle cells, such as v3, v5, and 51 (Reviewed by Rupp and 
Little (65)).  Integrins are also necessary for vascular development, as knockout of 
several integrin subunits (5, v, and 4) result in lethality prior to birth due to vascular 
defects (66-68).  ECM  components, such as fibronectin, vitronectin, laminin, collagen I 
and IV, and osteopontin are secreted from vascular cells and form a fibrillar network to 
which migrating and proliferating cells attach (69).  The presence of several of these 
matrix proteins is necessary for development, as germline deletion of fibronectin, 
laminin, or collagen IV results in embryonic lethality in mice (70-73).   
 Binding of an ECM ligand to its appropriate receptor integrin triggers a host of 
downstream signaling pathways.  Following integrin engagement, integrins cluster and 
cause intracellular phosphorylation of specific proteins.  One such protein under close 
study is focal adhesion kinase (FAK) which is strongly activated by all 1,3,5 integrin 
receptors.   
 
Structure and Function of Focal Adhesion Kinase 
 
FAK is a ubiquitously expressed non-receptor tyrosine kinase (125 kDa) present 
at focal adhesions (sites of cell contact to extracellular matrix). There are four major 
molecular domains of FAK that determine its function: an N-terminal integrin and 
receptor binding domain, a kinase domain, a proline rich domain containing binding sites 
for SH3 domains, and a C-terminal focal adhesion targeting (FAT) domain (illustrated in 
Figure 1.1) (74).  Within FAK, there are six tyrosine residues that can be phosphorylated 
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(75).  Among these six tyrosines, Y397 is critical for activation of FAK (76).  This 
residue is auto-phosphorylated by at least one of several mechanisms, thus creating a 
binding site for a number of proteins that contain SH2 domains (75).  FAK can be 
activated by signals from numerus extracellular stimuli, including ECM components, 
growth factors such as PDGF, and G-protein coupled receptor agonists such as 
angiotensin II (5, 77-80).  FAK activation from these upstream signals can lead to 
subsequent activation of both the Rac-Pak-JNK pathway and the Ras-MEK-ERK 
pathway (81, 82). 
 
FAK in the Vasculature 
 
Although FAK is ubiquitously expressed, recent evidence has implicated its 
importance in smooth muscle cells for the processes of vessel development, pathological 
growth, and contraction.  When FAK-deficient mice were generated by inserting a 
neomycin resistance gene into the beginning of the kinase domain, homozygous mice 
were unable to survive past embryonic day 8 (83, 84).  While FAK-deficient embryos 
implanted and gastrulated normally, they exhibited growth defects in the anteroposterior 
axis and poor mesodermal development (84).  Although vasculogenesis appeared normal 
prior to E7.5, the dorsal aorta and enteric arteries failed to develop properly after E8 (84).  
Our lab and others have shown that in vitro, there is evidence that activation of FAK is 
required for PDGF-BB stimulated migration and proliferation of VSMC, processes that 
are involved in the vascular injury response and pathological states such as 
atherosclerosis (78, 85).  There is also evidence that implicates FAK in the regulation of 
VSMC contractility (86).  Prior studies indicated that integrins on the cell surface of 
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VSMC can act as mechanotransducers and sense changes in stretch (87, 88).  
Additionally, FAK activation by phosphorylation at Y397 through treatment with 
angiotensin II has been observed specifically in VSMC (79).  Furthermore, a role for 
FAK in regulating contractility is demonstrated that pre-treatment with an antibody to 
FAK inhibits integrin-mediated increases in Ca2+ current (89).   
Within this body of literature, a role for FAK in several VSMC processes is 
emerging, and with it the possibility of unique regulation by its endogenous inhibitor, 
FRNK, discussed below. 
 
FRNK: AN ENDOGENOUS INHIBITOR OF FOCAL ADHESION KINASE 
 
FRNK Acts as a Dominant Negative to Block FAK Activity 
 
FRNK, a 43 kDa protein, is identical to the carboxy-terminus of FAK and is under 
the control of an alternative promoter within fak, discussed in greater detail below (90, 
91).  FRNK lacks the kinase domain and integrin and receptor binding sites, but contains 
proline-rich sites for SH3 domain binding.  Since FRNK also still contains the focal 
adhesion targeting domain (FAT), it is able to localize to sties of focal adhesions (Figure 
1.1) (90).  It is thought that when FRNK is present at focal adhesions, it is able to 
compete for proteins that bind the C-terminus of FAK.  Our lab, along with others, have 
demonstrated that FRNK can attenuate FAK activation by inhibiting phosphorylation at 
Y397 (78).  It is interesting to note that following FAK activation by integrin binding to 
fibronectin, that FRNK is also phosphorylated, likely affecting FRNK’s ability to bind 
other cellular proteins (90).  In addition, phosphorylation of FRNK can occur at serine 
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residues 148 and 151 after activation of protein kinase A (92).  More studies are required 
to address the mechanism by which FRNK regulates FAK activity.  
 
FRNK is Specific to Vascular Smooth Muscle 
 
Previous studies from our laboratory have revealed that FRNK is selectively 
expressed in vascular smooth muscle cells of large conduit arteries and in vascular and 
airway smooth muscle cells of the lungs (93).  This selective expression of FRNK in 
VSMC is likely important in vascular injury and during development, since FRNK is 
upregulated during these processes (93).  Specifically, levels of FRNK are low prior to 
surgeries and increase to robust levels 14 days post-endovascular injury in rat carotid 
arteries.  FRNK levels return to baseline at 21 days, as smooth muscle cell proliferation 
decreases (93).  Increased levels of FRNK protein are also observed between 4 and 14 
days following birth in rat (93).  Interestingly, these time points correlate with the 
transition of vascular smooth muscle cells from a proliferative to contractile phenotype, 
indicating that FRNK may serve to buffer FAK-dependent proliferative signals while 
enhancing vascular smooth muscle differentiation (94, 95).  Indeed, our laboratory has 
found that ectopic overexpression of FRNK attenuates FAK-dependent PDGF-BB- and 
angiotensin II-stimulated VSMC proliferation (78).  
 
FRNK Expression is Regulated by an Alternate Promoter within a FAK Intron 
 
 Previous work from Nolan and colleagues has shown that FAK activity is 
regulated by FRNK in a manner distinct from other tyrosine kinases (91).  As illustrated 
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in Figure 2.1, FRNK is expressed as a gene within a gene.  A FRNK-specific leader 
sequence and a region that exhibits promoter activity exist inside the fak intron 
immediately following the last exon of the kinase domain.  Dependent upon organism, 
this fak intron ranges in length from 15 to 21 kb.  RNase protection assays demonstrate 
that there are four FRNK RNA species expressed in abundance in FRNK-expressing cell 
types (91).     
Recently, Hayasaka, et al. demonstrated that a construct containing 6 kb of the 
mouse promoter region (-5338 to +730, relative to first nucleotide of the FRNK 5’ leader 
exon) drives arterial smooth muscle specific expression of a lacZ reporter gene in vivo 
(96).  LacZ expression was observed in major conduit arteries, including the pulmonary 
artery and aorta, and in resistance vessels of the lung, stomach, intestine, brain, and 
kidney (96).  This transgenic mouse also exhibited increased promoter activity in the 
medial layer of the carotid artery 14 days after endovascular injury (96).  Finally, the 
authors identified a ~100 bp sequence within the FRNK promoter that was necessary for 
luciferase expression in differentiated P19 cells (96).  This sequence is  responsive to AP-
1 and NF-E2 transcription factors and is identified here in Chapter II as a highly 
conserved element within the FRNK promoter. 
 
Expression of FRNK is Independent of Serum Response Factor 
 
A search for cis elements conserved from chicken to human did not reveal any 
conserved CArG elements.  However, a non-canonical CArG element was identified 75 
bp upstream of the mouse FRNK initiation site.  A similar variant has been identified in 
other smooth muscle specific genes, however usually more than one CArG box is 
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required to confer specificity, (47).  My studies described in this chapter indicate that 
smooth muscle-specific FRNK expression is a CArG-independent event. 
Other DNA response elements have been implicated in regulating smooth muscle 
specific expression in concert with the CArG element.  Mutation of the TGF- control 
element [TCE; G(A/C)GT(T/G)GG(T/G)GA)] disrupts expression of smooth muscle -
actin and SM-22, as does mutation of E-box elements (CAnnTG motifs) (97-99).  Aortic 
carboxypeptidase-like protein (ACLP) is an example of a smooth muscle-specific gene 
that is CArG-independent (100).  ACLP exhibits an expression profile similar to that of 
FRNK, with protein levels increasing in VSMC after carotid artery ligation, while 
canonical smooth muscle genes decrease (100).  ACLP is also SRF-independent; rather, 
its promoter is activated by transcription factors Sp1 and Sp3 (100).  VSMC-specific 
expression of cysteine-rich protein 2 (CRP2)  is dependent upon an 800 bp region of its 
promoter that is CArG-independent (101).  Unlike ACLP, this region of the CRP2 
promoter appears to be independent of Sp1 and Sp3 (101).  Interestingly, CRP2 
expression seems to be limited to arterial smooth muscle, much like promoter activity of 
the 6kb FRNK lacZ promoter mouse (96, 101).  Recently, Lin, et al. showed that 
expression of CRP2 in vascular smooth muscle cells is dependent on TGF- mediated 
activation of ATF2 (102).  Although the histidine-rich calcium-binding protein (HRCBP) 
is expressed in all three muscle types (skeletal, cardiac, and smooth) it constitutes another 
example of a smooth muscle-selective protein expressed in a CArG-independent fashion 
(103).  Expression of HRCBP in calciosomes of smooth muscle cells is dependent on a 
highly conserved myocyte enhancer factor 2 (MEF2) site within the promoter (103).  
Other CArG-independent smooth muscle genes include Notch3 and APEG1 (104).  My 
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efforts to identify the mechanisms that regulate expression of FRNK are detailed in 
Chapter II.   
 
STATEMENT OF PURPOSE 
  
 Since in vivo models have demonstrated that signaling through FAK is essential 
for development of the vasculature, it is necessary to study the specific FAK-mediated 
processes that allow proper smooth muscle cell growth.  This work provides evidence 
that FAK signaling is important in regulating smooth muscle cell phenotype in vivo.   
 Prior to this work, little was known about the mechanisms that regulate FRNK 
expression in smooth muscle cells.  Within Chapter II, I describe my analysis of the 
FRNK promoter, within which I identified matrix components that regulate FRNK 
expression.  In addition, my study of the promoter revealed conserved elements that 
confer smooth muscle specificity.  In addition, since my analysis of the FRNK promoter 
has indicated that expression of FRNK is dependent on transcription factors other than 
SRF, this work begins to assess the novel smooth muscle specific transcriptional 
mechanisms that regulate FRNK expression. 
Our lab has previously shown that FRNK is capable of attenuating FAK-
dependent migration and proliferation in smooth muscle cells, similar to its behavior 
when ectopically expressed in other cell types.  This work specifically addresses the role 
of FRNK in vivo, which beforehand was largely unknown.  Herein, I have tested the 
hypothesis that FRNK is a negative regulator of focal adhesion kinase, and that 
expression of FRNK in smooth muscle cells acts to decrease smooth muscle cell 
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proliferation and migration while concurrently promoting smooth muscle cell 
differentiation.  Indeed, the studies described here utilize in vivo and in vitro models and 
show that in the absence of FRNK, smooth muscle gene expression is attenuated 
Germline deletion of FAK results in early embryonic lethality, as described 
previously.  Since vasculogenesis is incomplete at this point, an alternative model was 
needed to characterize the role of FAK in development of the vasculature.  Within 
Chapter IV, I characterized the role of FAK in formation of the cardiac outflow tract and 
in aorticopulmonary septation.  Since FAK has been implicated as a regulator of 
differentiation in other cell types, we hypothesized that would be true in cardiac neural 
crest-derived smooth muscle cells. 
In general, this study contributes to the understanding of FAK and FRNK in 
regulating smooth muscle cell processes. 
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Figure 1.1.  Focal adhesion kinase domains.   
CHAPTER II 
 
ANALYSIS OF THE FRNK PROMOTER 
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INTRODUCTION 
 
Previous studies have demonstrated that FRNK is expressed as a unique protein 
product from the fak gene, under the control of an internal promoter (91).  Within exons 
21 and 22 of the fak intron (15 to 21 kb, dependent on species) immediately following the 
last exon of the kinase domain, there is a FRNK-specific leader sequence only observed 
in FRNK cDNA.  Adjacent to this leader sequence is a 5’ non-coding region exhibiting 
promoter activity.  Our group recently showed that FRNK expression is limited to smooth 
muscle tissues and is regulated temporally both during development and following injury 
in the vasculature (93).  Nolan, et al. showed that a 2.4 kb region of the chicken fak intron 
is capable of directing luciferase reporter expression in chicken embryonic fibroblasts 
(91).  Likewise, Hayasaka and colleagues demonstrated that a construct containing 6 kb 
of the mouse promoter region (-5338 to +730, relative to first nucleotide of the FRNK 5’ 
leader exon) drives arterial smooth muscle specific expression of a LacZ reporter gene in 
vivo (96).  The authors observed LacZ expression in major conduit arteries including the 
pulmonary artery and aorta and in resistance vessels of the lung, stomach, intestine, brain, 
and kidney (96).  This promoter-reporter transgenic mouse also exhibits increased LacZ 
expression in the medial layer of the carotid artery 14 days post-endovascular injury (93, 
96).  These results were consistent with our own in vivo studies and demonstrate that a 
6kb region of the fak intron is required for smooth muscle-specific expression of FRNK. 
 The study of smooth muscle specific gene expression has most closely examined 
the role of serum response factor (SRF) in regulating transcription of contractile genes.  
Expression of genes such as SM -actin and SM-myosin heavy chain require the binding 
of SRF to  one or more CArG elements within their promoter, as mutation of the CArG 
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motif (CC(AT)6GG) results in disruption of expression (38, 42-47).  In the smooth 
muscle -actin gene, mutation of any of the three CArG elements present within the 
promoter resulted in no activity in a transgenic LacZ reporter mouse (43).  This is also 
true of mutations made to CArG elements within the SM-22, SM-MHC, and desmin 
promoters (42, 44, 45, 48).  Recent data indicates that smooth muscle-specific, SRF-
dependent gene expression is likely regulated by binding of coactivators to SRF, 
including myocardin and mycoardin-related transcription factors-A and –B (MRTF-A 
and -B) (105-107).  It is also interesting to note that even though CArG-dependent 
smooth muscle specific expression is well described, recent work has determined that 
myocardin, while required for complete maturation of smooth muscle cells, is not 
sufficient for smooth muscle cell specification (50).  Therefore, elements responsible for 
smooth muscle-specific expression are still at large. 
Other DNA response elements have been implicated in regulating smooth muscle 
specific expression in the absence of the CArG element.  Independent of SRF binding, 
the ACLP promoter is activated by transcription factors Sp1 and Sp3 (100).  In addition, 
cysteine-rich protein 2 (CRP2) is also CArG-independent and exhibits expression 
patterns similar to those seen with FRNK (101).  VSMC-specific expression of CRP2 is 
dependent upon an 800 bp region of its promoter and unlike ACLP, this region of the 
CRP2 promoter also appears to be independent of Sp1 and Sp3 (101).  Interestingly, 
CRP2 expression seems to be limited to arterial smooth muscle, much like the 6kb 
regions of the FRNK promoter (96, 101).   Even though a collection of CArG-
independent mechanisms for smooth muscle-specific gene expression has emerged from 
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the literature, our preliminary evidence has indicated that these mechanisms do not play a 
role in regulation of FRNK promoter activity. 
For several reasons, we wanted to explore further what regulates FRNK 
expression: 1) FRNK is highly expressed during postnatal development and following 
injury and 2) FRNK is selectively expressed in smooth muscle cells with the absence of 
conserved CArG elements.  Thus, we used the FRNK promoter to determine potential 
regulators.  In addition to identifying matrix proteins and growth factors that regulate 
FRNK expression levels, here we have also identified highly conserved promoter 
elements and characterized their response to the differentiation agonist TGF-.  Finally, 
we used a recently described mammalian-cell based assay to screen a mouse cDNA 
library for potential regulators of the FRNK promoter (108). 
 
 27
MATERIALS AND METHODS 
 
Cell Culture, Transfections, and Reporter Assays 
 Aortic vascular smooth muscle cells were cultured from rats using enzymatic 
digestion (34).  Aortas from 6-8 rats were dissected and stripped of adventitial fat.  
Following enzymatic digestion, the adventitia and endothelium were stripped from each 
vessel.  After a second enzymatic digestion, cells were maintained in Delbucco’s 
modified eagle medium with F12 supplemented with 10% fetal bovine serum and 0.5% 
penicillin/streptomycin and used from passage 8-16.  Cos, NIH-3T3, 10T1/2, and A7r5 
cells were obtained through ATCC and were maintained in Delbucco’s modified eagle 
medium supplemented as above.  SRF-/- cells were a generous gift from Albert Nordheim 
and maintained on 0.1% gelatin coated plates in DMEM plus 15% ES Qualified FBS, 
50U/mL penicillin, 50μg/mL streptomycin, 0.1mM β- mercaptoethanol, and 1000U/mL 
Leukemia Inhibitory Factor (LIF).   
 Matrigel (Becton-Dickinson) was diluted 1:3 in ice cold phosphate buffered 
saline, applied to pre-chilled plastic tissue culture plates, and allowed to polymerize at 
37oC for one hour.  Fibronectin (Sigma) was diluted in phosphate buffered saline to 
10g/mL and coated on plates overnight at 4oC.  Cells were treated with TGF- 
(Chemicon) at 1 ng/mL.   
For overexpression, constructs were transfected into cells using GeneJammer 
(Stratagene), SuperFect (Qiagen), or TransIT-LT1 (Mirus) transfection reagent  
according to the manufacturer’s instructions.  Following transfection, cells were lysed in 
Glo Lysis Buffer and assayed using Steady Glo Luciferase Assay system (Promega) as 
directed by the manufacturer.  
 28
 
Real-Time Quantitative RT-PCR 
Cells were lysed in TRIzol (Invitrogen) and total RNA was isolated accoroding to 
the manufacturer’s protocol.  Expression was measured using the ABI Prism 7700 or 
7500 TaqMan system.  Primers and fluorescent probes were designed for the following 
genes: FRNK (Forward: GCTGCATTCTGAGGCGTTTA, Reverse: 
CAGGATTGTGCACCACCAG, Probe: AGCCAGGACTGAGACGCCGCC) and FAK 
(Forward: GAAAGCAGTAGTGAGCCAACC, Reverse: 
GAGACTGTCCACTATCTTCTG, Probe: CTCCATGCCTGATAATACTGGCCCAG).  
18S primers and probes were a generous gift from Hyung-Suk Kim. 
 
Western Analysis 
To examine protein levels, cells were lysed in RIPA buffer with protease and 
phosphatase inhibitors as previously described (78).  Protein concentration of lysates was 
determined by using a colormetric BCA assay (Pierce).   Lysates were electrophoresed on 
an 11% polyacrylamide gel, transferred to nitrocellulose, and immunoblotted with an 
antibody directed towards the c-terminus of FAK (Upstate). 
 
Generation of Constructs 
 To generate deletion mutants, PCR mutagenesis was utilized.  Briefly, forward 
and reverse primers were designed starting approximately 20 bp preceding and following 
the deletion site, excluding the deletion site.  PCR was performed using cloned Pfu and 
guidelines from the Stratagene Quickchange mutagenesis kit.  To generate TK-luciferase 
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and -galactosidase constructs, primers were designed to add either BglII or KpnI 5’ or 3’ 
overhangs to PCR amplicons corresponding to the DNA region of interest.  TK-luciferase 
or NotILacZ was cut at the multiple cloning site with BglII and KpnI and re-ligated with 
the PCR amplicons.  
 
Mammalian Cell Screen 
Our screen of mammalian cells for activation of PeakA/B-luciferase was modified 
from an assay previously described by Chang, et al (109).  We obtained an E13.5 mouse 
cDNA library from Invitrogen and amplified the library on approximately one hundred 
150mm plates.  Colonies were allowed to grow overnight at 25oC and were subsequently 
washed off the plates and pooled in LB broth.  DNA was prepared by using a GigaPrep 
kit (Sigma).  Following resuspension, DNA was divided into approximately 900 aliquots.  
300 ng of each aliquot was singly transfected in to Cos cells plated in 24 wells along with 
150 ng of PeakA/B-luc and 50 ng of SV40--gal (internal control).  Each well was 
assayed 24 hours following transfection for luciferase and -gal activity (first round).  
After normalization to -gal activity and empty vector, those aliquots which fell in the 
top 10th percentile for activity were retransfected in triplicate.  From this round, ten 
aliquots were chosen that exhibited the most significant increase in promoter activity 
(second round).  These pools were retransformed, and DNA was isolated by alkaline lysis 
and isopropanol precipation from 24 separate pools of approximately 20 colonies for each 
aliquot.  This DNA (third round), was subsequently transfected into Cos cells and 
assayed as described above.  Those pools that exhibited significant activity were 
retransformed.  Individual colonies were selected, cultured, lysed for isolation of DNA.  
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The DNA from these individual colonies was transfected into Cos cells and assays were 
performed as above.  The 95 colonies with the most significant increase in promoter 
activity were selected for high-throughput DNA sequencing (UNC Genome Anlaysis 
Facility).  The sequences were then compared to the entire mouse genome (using NCBI 
Blast) for identification. 
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RESULTS 
 
FRNK promoter activity is specific to smooth muscle cells and independent of 
activation by serum response factor 
 
 Previous work showed that vascular specific expression of FRNK is under the 
control of a fak intron, diagrammed in Figure 2.1A (91, 96).  To investigate what factors 
regulate transcription of FRNK, we utilized a promoter-reporter construct in which 6kb 
of the FRNK promoter drives expression of luciferase.  Since we previously reported that 
FRNK expression is specific to smooth muscle containing tissues in the rat (93),  we 
chose to investigate the activity of this promoter in cell types with varying degrees of 
likeness to primary cultured smooth muscle cells.  In comparison with other cell types, 
primary cultured vascular smooth muscle cells (VSMC) exhibited promoter activity over 
twenty-fold that of 3T3 fibroblasts (Figure 2.1B).  Sequence analysis revealed that the 
FRNK promoter did contain a nearly conserved CArG element.  To test whether the 
FRNK promoter activity was dependent upon binding of SRF, we measured the activity 
of the FRNK promoter in SRF-/- embryonic stem cells.  In contrast to the smooth muscle 
-actin promoter, the activity of the FRNK promoter was not upregulated in response to 
re-expression of wild type SRF (Figure 2.1C). 
 
Expression of FRNK is regulated by components of the extracellular matrix 
 Since we established that FRNK expression is limited to smooth muscle tissues 
and is regulated during development and injury, we sought to identify distinct factors that 
control expression.  In addition to testing the effects of various growth factors on FRNK 
expression (TGF-, Angiotensin II, PDGF, described in chapter III), we also looked at 
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the ability of extracellular matrix proteins to regulate FRNK expression.  After 24 hours, 
VSMC plated on Matrigel had significantly lower levels of FRNK promoter activity in 
comparison with the uncoated control (Figure 2.2A).  Likewise, we also observed 
decreased levels of FRNK mRNA in VSMC plated on either type of Matrigel for 24 
hours (Figure 2.2B).  Using an antibody specific for the C-terminus of FAK that detects 
both FAK and FRNK, we found that VSMC plated on Matrigel exhibited decreased 
levels of FRNK protein starting at only 12 hours post-plating.  By 48 hours, FRNK 
protein was almost completely absent (Figure 2.2C).  In subsequent experiments, we 
sought to identify the specific elements within the extracellular matrix that were 
responsible for the observed decrease in FRNK expression.  Promoter assays in which 
cells have been plated on specific ECM components revealed a small, yet consistent, 
decrease in FRNK promoter activity in response to laminin, but no response to collagen 
IV or fibronectin (data not shown). 
 
The FRNK promoter contains two highly conserved regions that are necessary and 
sufficient for smooth muscle-specific activity 
 
 Our earlier studies demonstrated robust changes in FRNK expression during 
development and following vascular injury.  Although our initial experiments revealed 
extrinsic modulators of FRNK expression, we have not yet identified a transcription 
factor capable of increasing FRNK expression to the level seen following vascular injury.  
Therefore, we employed a method of conservation analysis to identify regions of the 
FRNK promoter that may have particular importance in regulating smooth muscle-
specific expression of FRNK.  Using VISTA, a web-based sequence analysis tool, we 
aligned the FAK intron that contains the FRNK-specific exon from mouse, rat and human 
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(110, 111).   This analysis revealed two regions over 75% conserved (termed Peak A and 
Peak B) that are contained within the 6kb region of the FRNK promoter under study 
(Figure 2.3A).  Peak A is approximately 220 bp in length and appears as a doublet, while 
Peak B is only 130 bp in length.  As expected, high levels of conservation were also 
observed between the FRNK-specific exon and the first exon that FRNK and FAK have 
in common.  An additional conserved region was identified further away from the FRNK 
start site that is not contained within the 5kb promoter region of interest (data not shown). 
 To determine if these highly conserved regions were necessary for regulation of 
FRNK expression, I designed a series of promoter-reporter constructs in which the 
conserved regions identified from the VISTA screen were deleted from our 6kb promoter 
fragment (Figure 2.3B).  In addition, we also generated promoter-constructs in which the 
highly conserved regions were used to drive expression of luciferase on their own.   
Likewise, we generated a construct in which both regions were cloned together in tandem 
into one promoter-reporter (Figure 2.3B). 
 To test whether these conserved elements were necessary for smooth muscle 
specific FRNK promoter activity in vitro, I transfected NIH-3T3 fibroblasts, bovine 
endothelial cells, and primary cultured aortic VSMC with each of the aforementioned 
constructs (Figure 2.4A).  In NIH-3T3 cells, the FRNK promoter had relatively low 
activity which was mostly unchanged with deletion of either Peak A, Peak A1, Peak A2, 
or Peak B.  In contrast, smooth muscle cells showed robust activation of the wild type 
FRNK promoter, and this activity was significantly reduced by deletion of any one of the 
conserved regions.  Bovine endothelial cells had relatively low levels of wild type FRNK 
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promoter activity, but with deletion of Peak A1, Peak A2, or Peak B, promoter activity 
was significantly increased (Figure 2.4A). 
 I also demonstrated that these conserved elements can drive luciferase expression 
on their own in VSMC.  Transfection of constructs containing each element combined 
with a minimal promoter (TK) resulted in luciferase activity 6-12 fold over control.  
Combination of Peak A and Peak B in the Peak A/B constructed resulted in promoter 
activity that was additive of each region alone (Figure 2.4B).   
 Since the Peak A/B construct appeared to be sufficient for VSMC-specific 
expression in culture, we next wanted to determine if that was true in an in vivo model. 
We generated transgenic Xenopus laevis that expressed dsRed under the control of 
PeakA/B.  Expression during early stages prior to smooth muscle investment was 
obsereved in the heart and somites (data not shown).  To test whether these elements 
were sufficient for vascular-specific expression in a mammalian model, we generated 
several lines of transgenic mice containing a transgene that contained Peak A and B in 
tandem driving expression of -galactosidase (Figure 2.4C).  Unfortunately to date, we 
have been unable to show that any of the 7 founder lines we generated expresses the 
transgene, indicating that these elements are likely insufficient for complete promoter 
activity in the vasculature. 
 
Conserved FRNK promoter elements are not responsive to TGF-
 Other studies on the FRNK promoter (described in Chapter III), have shown that 
in 10T1/2 cells, FRNK promoter activity is increased by approximately 2-fold in 
response to treatment with TGF-.  Although this response is relatively modest, 
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endogenous mRNA and protein exhibited greater response to TGF-, possibly due to 
additional TGF- responsive elements outside of the 6kb promoter construct.  To test 
whether or not the conserved elements we identified were responsible for this response, 
we transfected the deletion constructs and minimal promoter constructs into 10T1/2 cells 
and treated these cells with TGF- (1 ng/mL).  24 hours following treatment, we 
observed the expected two-fold increase in wild type promoter activity in response to 
TGF-(Figure 2.5A)Although it was not significant, activity of the mutant promoters 
still appeared to increase(Figure 2.5A).  In addition, we also transfected the minimal 
promoter constructs containing Peak A and/or Peak B and found that on their own, none 
of these constructs showed any response to TGF- (Figure 2.5B).  Taken together, these 
data indicate that the TGF- responsive elements within the FRNK promoter are not 
located within the conserved regions we identified.  At this point, our data does not 
clearly indicate whether this response is dependent on Smad activity or on other known 
downstream pathways such as p38 or ATF2. 
 
An important element lies within the 5’ end of the FRNK promoter 
 We also chose to look for responsive elements by making serial truncations of the 
FRNK promoter (Figure 2.6A).  In VSMC, we found that deletion of the first 1000 bp of 
the 5kb FRNK promoter resulted in no significant change in promoter activity, but that 
subsequent truncations caused a steady decline in luciferase expression (Figure 2.6B).  It 
will be interesting to test whether any of the truncations cause a differential response to 
TGF-. 
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Identification of possible activators of the conserved elements of the FRNK promoter 
using a luciferase-based mammalian cell screen 
 
Our studies revealed that the conserved regions of the FRNK promoter that we 
identified from the VISTA screen were necessary and sufficient for smooth muscle 
specific activity in vitro, but that these elements were not responsive to TGF-.  In an 
attempt to determine what transcriptional coactivators or upstream signals are responsible 
for the inherent promoter activity of these conserved elements, we screened a cDNA 
library made from E13.5 mouse embryo for proteins that resulted in increased activation 
of Peak A/B-luciferase.  Figure 2.7 shows representative results from the screen.  
Following sib-selection of individual clones, we sequenced positive scoring clones.  A 
table of identified clones that activated the promoter is shown in Table 2.1. 
 
 37
DISCUSSION 
 
Our analysis of the FRNK promoter has provided several findings regarding its 
specific activity in smooth muscle cells.  Previous work indicated that FRNK expression 
was differentially controlled in smooth muscle cells during vascular development and 
also in the response to guide-wire mediated injury of the carotid (93).  Prior analysis of 
the FRNK promoter yielded a 6kb region that resulted in vascular specific expression (91, 
96).  In this study, we were able to (1) identify specific factors that down-regulate FRNK 
expression, (2) isolate small, highly conserved regions of the FRNK promoter that are 
necessary and sufficient for in vitro smooth muscle-specificity, and (3) screen for 
potential activators of the FRNK promoter. 
 As discussed previously, the expression of most smooth muscle genes has been 
well described, and is thought to be under the control of SRF binding to CArG boxes 
embedded within the promoters.  The FRNK promoter does contain an unconserved 
CArG-like element and other non-consensus CArG boxes have shown to be responsive to 
SRF.  We found that re-expression of SRF in SRF-/- embryonic stem cells did not induce 
the FRNK promoter, while SRF-dependent activity of the SM a-actin promoter increased 
by over 10-fold.  This confirmed that indeed, the FRNK promoter did not rely on this 
mechanism of smooth muscle-specific gene expression. 
 In 2003, Walker, et al. published results indicating that both Matrigel and 
perlacan, a heparin sulfate proteoglycan had the ability to upregulate levels of FRNK 
promoter activity and FRNK protein levels (112).  The authors observed increases in 
FRNK protein in smooth muscle cells plated on Matrigel for four hours in comparison to 
cells plated on fibronectin (112).  This group also looked at the activity of a portion of the 
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FRNK promoter and found that in comparison to the control, it was more active in A10 
smooth muscle cells plated on perlecan or Matrigel (112).  However, the construct used 
in their experiment was not the entire portion shown by Hayasaka, et al. to direct vascular 
specific expression, but a smaller 2.4 kb portion that exhibits promiscuous activity in 
fibroblasts (91, 96).  In our study, we looked at levels of FRNK promoter activity, 
mRNA, and total protein in response to plating on Matrigel in comparison to tissue 
culture plastic.  We found that in general, plating smooth muscle cells on Matrigel for an 
extended amount of time resulted in decreased FRNK promoter activity and expression 
(Figure 2.2).  Preliminary data from luciferase reporter assays also indicate that this may 
be due to the high concentration of laminin present in Matrigel (data not shown).  Our 
results support our hypothesis that FRNK expression is regulated by the environment of 
smooth muscle cells in vessels.  The composition of Matrigel (mostly laminin and 
collagen IV) mimics the environment of a mature, quiescent vessel.  We have proposed 
that FRNK expression is upregulated during injury and development to act as a negative 
regulator of proliferative signaling through FAK.  In a mature vessel, FRNK expression 
would likely be unnecessary, since smooth muscle cells are mostly quiescent and their 
rate of proliferation is too low to require regulation.  Therefore, we were not surprised 
that primary cultured smooth muscle cells (with a tendency to be highly proliferative), 
gradually showed decreased expression of FRNK protein in response to the matrix 
environment.  This hypothesis is consistent with other results discussed herein that show 
increased promoter activity, mRNA, and protein levels in response to TGF-.  TGF- is 
an agonist involved in differentiation of smooth muscle cells and is highly expressed in 
the vasculature during development and following vascular injury.  Early vascular 
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development and injury repair are distinct times in which vascular smooth muscle cells 
are encouraged by extracellular cues to proliferate and it is after these times that we 
hypothesize FRNK is being turned on to act as a negative regulator of smooth muscle cell 
proliferation, perhaps to aid in transition to a mature, contractile phenotype. 
 Although our findings that FRNK promoter activity is modulated by extracellular 
matrix and growth factors are significant, they do not fully detail the regulation of the 
FRNK promoter.  For this reason, we chose to analyze the full intronic region of the fak 
gene containing the FRNK promoter to identify the most highly conserved regions.  
Other groups have taken a similar approach and have identified novel CArG-independent 
mechanisms of smooth muscle-specific expression (103).  We identified two separate 
regions that were over 75% conserved between mouse, rat, and human (Figure 2.3).  
Among these two regions, Peak B had been previously identified by truncation analysis 
of the promoter by Hayasaka, et al. (96).   In addition, they also showed that mutation of 
this region attenuated binding of AP-1 and NF-E2 enhancers (96).  Our studies have 
demonstrated that the two elements we identified, Peak A and Peak B, are necessary and 
sufficient for smooth muscle specific promoter activity in vitro (Figure 2.4).  We found 
that deletion of either element had a dramatic effect on promoter activity.  When we 
looked at the inherent promoter activity of each of these regions individually in smooth 
muscle cells, we found that stringing Peak A and B together in tandem to drive luciferase 
expression resulted in an additive increase in activity (Figure 2.4).  Interestingly, we also 
found that deletion of certain portions of the conserved elements resulted in increased 
promoter activity in bovine endothelial cells, indicting that these regions may have 
repressor activity in non-smooth muscle cell types (Figure 2.4A). 
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 We next strove to determine if these elements regulate in vivo expression of 
FRNK.  Our initial attempts at answering this question have been unsuccessful thus far.  
To study whether these elements were sufficient to drive vascular specific expression of 
LacZ in the mammal, we generated a transgenic promoter reporter mouse model.  The 
transgene we designed contained Peaks A and B in tandem directing expression of LacZ.  
Although we had seven mouse lines that contained the transgene, we were unable to 
determine if any of these founder lines actually expressed LacZ or if we were unable to 
detect LacZ.  More intricate experimental design will be required to develop additional 
transgenic models that will more directly answer this question.  Specifically, an approach 
that determines whether these elements are necessary for smooth muscle-specific 
expression of FRNK will likely be successful.  Future experiments will involve 
generating transgenic mice that contain the entire 6kb FRNK promoter driving LacZ 
expression with each conserved region deleted from the promoter.   
 During our study of the promoter, TGF- emerged as a growth factor that 
increases FRNK expression.  Our results indicated that deletion of either conserved 
element within the FRNK promoter does not alter the response to TGF-.  Our 
preliminary studies suggest that Activity of the promoter also appears to be independent 
of the Smad signaling pathway (data not shown).  Analysis of the FRNK promoter for 
other published consensus sites for alternative downstream targets of TGF- has not 
yielded any possibilities for this mechanism.  To delineate other regions of the FRNK 
promoter that is are smooth muscle-specific, we truncated the FRNK promoter from the 
5’ end approximately 1 kb at a time. With deletion of the first 1950 bp, we did see a 
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significant decrease in promoter activity.  Ongoing studies include further analysis of this 
950 bp region to determine whether it is responsive to TGF-.   
 Since our studies have not revealed what mechanism regulates the conserved 
regions within the FRNK promoter, we undertook a major effort to uncover novel 
regulators of these elements.  We utilized a mammalian cell line and a widely used and 
highly repeatable assay system to screen an E13.5 mouse cDNA library for potential 
coactivators and enhancers of the FRNK promoter.  From this screen, we were able to 
generate a list of genes that activated identified conserved elements (Table 2.1).  
However, we were surprised that within the list of known genes from our screen, no 
known transcription factors were identified.  One caveat of this study was that all assays 
were performed in Cos cells, a cell line that most likely exhibits transcriptional signaling 
pathways differing from vascular smooth muscle cells.  There were several unknown 
genes in the screen that repeatedly activated the Peak A/B construct nearly 20-fold.  As 
more information in the mouse genome becomes available, it will be valuable to research 
the database for possible matches for these genes. 
 In conclusion, our analysis of the FRNK promoter has developed multiple paths 
for future study of smooth muscle-specific regulation of FRNK.  This work has shown 
that regulation of the FRNK promoter is quite complex and not only involved regulation 
by known matrix proteins and growth factors, but possibly contains unique, unstudied 
elements that may lead to the discovery of novel mechanisms of CArG-independent 
smooth muscle-specific gene expression. 
 42
Table 2.1: Selected enhancers of Peak A/B-luc identified from screen. 
Name of Gene Fold Increase
ARP2 actin-related protein 2 homolog >7 
Isocitrate dehydrogenase 3 (NAD+) alpha >14 
Secret frizzled-realted protein 2 >17 
RIKEN cDNA 2610203C20 gene >13 
LMBR1 domain containing 1 >18 
Tubby candidate gene >18 
Suppressor of zeste12 homolog >15 
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Figure 2.1.  An intronic region of FAK contains smooth muscle-specific, CArG-independent 
FRNK promoter activity.  A. Schematic showing that a FRNK specific exon lies within an 
intron of the FAK gene.  The blue regions indicate those exons contained by FAK alone, the 
green region indicates the single FRNK-specific exon, and the red region indicated the portion of 
the gene that FAK and FRNK share.  A 6kb region containing the FRNK-specific exon (shown at 
bottom of panel) is sufficient to regulate smooth muscle-specific expression in vivo.  A reporter 
plasmid expressing luciferase under the control of the before-mentioned 6kb piece is used to 
assay promoter activity in VSMC.  B. Activity of the 6kb FRNK promoter-luciferase construct in 
NIH-3T3 fibroblasts, 10T1/2 smooth muscle precursor cells, A7r5 cells, and primary cultured 
vascular smooth muscle cells (VSMC) normalized to minimal promoter activity.  C.  Activity of 
the FRNK promoter or smooth muscle -actin promoter in SRF-/- cells in response to addition of 
recombinant SRF.  Data is representative of at least 3 separate experiments and is expressed as 
the mean +/- SEM. 
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Figure 2.2.  VSMC plated on Matrigel exhibit reduced expression of FRNK.  A. Primary 
VSMC were transfected with FRNK-luc for 24 hours and subsequently trypsinized and plated on 
tissue culture plastic, Matrigel (MG), reduced growth factor Matrigel (RGF-MG), or fibronectin 
(FN) for 24 hours in serum-free media.  Cells were assayed for luciferase activity and data was 
normalized to control (plastic).  B. VSMC were maintained in serum-free media plated on either 
plastic, Matrigel, or growth factor reduced Matrigel for 24 hours.  Total RNA was isolated from 
resuspended cells and 250 ng was subjected to real time quantitative RT-PCR with primers and 
probes specific for the FRNK specific exon.  C. VSMC were harvested and plated for 4, 24, and 
48 hours on plastic dishes or dishes pre-coated with Matrigel or reduced growth factor Matrigel.  
The cells were lysed in RIPA buffer and protein content was determined.  100 g of protein was 
analyzed by gel electrophoresis followed by Western blotting with a C-terminal FAK-specific 
antibody. 
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Figure 2.3.  The FRNK promoter has two highly conserved regions.  A.  VISTA screen for 
homology within the FRNK promoter between mouse, rat, and human.  The region outlined in red 
is the exon common to both FRNK and FAK, green indicates the FRNK-specific exon, and 
regions in orange and purple are peaks over 75% homologous in human/mouse and human/rat 
alignments.  Pink shading indicates >75% homology.  B. FRNK promoter constructs with 
deletion/addition of Peaks A and B.   
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Figure 2.4.  Conserved regions of FRNK promoter are necessary and sufficient for smooth 
muscle specific FRNK-promoter activity in vitro.  A. NIH-3T3, bovine endothelial cells (BEC), 
or primary cultured vascular smooth muscle cells (SMC) were transfected with wild type or 
constructs with deletions of conserved regions driving luciferase expression.  Cells were 
maintained in media containing 10% FBS and assayed for promoter activity 48 hours following 
transfection.  Data is normalized to activity of a minimal promoter (TK).  B. Smooth muscle cells 
were transfected with constructs contained the 100-220 bp conserved regions either alone or in 
tandem.  Luciferase activity was determined 48 hours following transfection as described above.  
C. Diagram of construct used to generate transgenic promoter-reporter mouse line. 
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Figure 2.5.  Conserved regions of FRNK promoter do not contain elements responsive to 
TGF-.  A. 10T1/2 cells were transfected with either wild type or deletion constructs.  24 hours 
following transfection, cells were served in DMEM containing 0.2% FBS for 24 hours.  Cells 
were starved once more with 0.2% FBS for four hours and subsequently treated with TGF- (1 
ng/mL) for 24 hours.  Cells were assayed for luciferase activity and data is reported as relative 
activity compared to a minimal promoter (TK).  B. 10T1/2 cells were transfected with constructs 
containing the conserved regions of the FRNK promoter and were subsequently starved, treated 
with TGF-and assayed as described above.   
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Figure 2.6.  A region directing smooth muscle-specific expression lies within the 5’ end of 
the FRNK promoter.  A. Diagram showing serial truncation of the FRNK-luciferase promoter 
construct.  B. Primary cultured VSMC were transfected with wild type and truncated luciferase 
constructs and maintained in 10% FBS for 48 hours.  Cells were assayed for luciferase activity.  
Data is presented as fold over no treatment for each construct. 
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Figure 2.7. Luciferase based screen in mammalian cells for activators of the FRNK 
promoter.  A. Shown is example profile from pools of >100 colonies from E13.5 mouse library 
co-transfected with PeakA/B-luciferase in cos cells.  B. Peak A/B-luciferase was cotransfected 
with pools of 20 colonies sib-selected from original library pools (example profile).  C. 
Luciferase activity of individual colonies sib-selected from pools of 20 colonies.  All data is 
normalized to activity of empty vector control (example profile).  Bars containing darker filling 
indicate those pools or colonies that were picked for further study. 
 
CHAPTER III 
 
FRNK EXPRESSION PROMOTES SMOOTH MUSCLE CELL MATURATION DURING VASCULAR 
DEVELOPMENT AND FOLLOWING VASCULAR INJURY1 
                                                 
1 Re-submitted as presented here to Arteriosclerosis, Thrombosis, and Vascular Biology in July 2008 as: 
Rebecca L. Sayers, Liisa J. Sundberg-Smith, Mauricio Rojas, Haruko Hayasaka, J. Thomas Parsons, 
Christopher P. Mack, and Joan M. Taylor.  FRNK expression promotes smooth muscle cell maturation 
during vascular development and following vascular injury. 
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ABSTRACT 
 
Objective--Smooth muscle cell (SMC) differentiation is a dynamic process that must be 
tightly regulated for proper vascular development and to control the onset of vascular 
disease.  Our lab previously reported that a specific focal adhesion kinase (FAK) inhibitor 
termed FRNK (FAK Related Non-Kinase) is specifically expressed in large arterioles 
when SMC are transitioning from a synthetic to contractile phenotype and that FRNK 
inhibits FAK-dependent SMC proliferation and migration.  Herein, we sought to 
determine whether FRNK expression modulates SMC phenotypes in vivo. 
Methods and Results-- We present evidence that FRNK-/- mice exhibit attenuated SM 
marker gene expression during post-natal vessel growth and following vascular injury.  
We also show that FRNK expression is regulated by TGF- and that forced expression of 
FRNK in cultured cells induces serum- and TGF--stimulated SM marker gene 
expression, while FRNK deletion or expression of a constitutively activated FAK variant 
attenuated SM gene transcription.   
Conclusions--These data highlight the possibility that extrinsic signals regulate the SMC 
gene profile, at least in part, by modulating the expression of FRNK and that tight 
regulation of FAK activity by FRNK is important for proper SMC differentiation during 
development and following vascular injury. 
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INTRODUCTION 
 
While medial smooth muscle cells (SMC) found in the mature vessel are fully 
differentiated and express high levels of SM contractile proteins, these cells do not 
terminally differentiate and can transition to a synthetic phenotype characterized by low 
levels of SM contractile gene expression and responsiveness to pro-growth and migratory 
signals.  This unique plasticity is critical for proper vessel development, blood pressure 
homeostasis, and injury repair processes (47, 113). 
A number of secreted growth factors (i.e. platelet derived growth factor (PDGF-
BB), sphingosine 1-phosphate (S1P), transforming growth factor- (TGF-) and 
contractile agonists (angiotensin II, endothelin-1 and thrombin) have been shown to 
regulate SMC phenotype in vitro and in vivo (58).  In addition to levels of circulating 
factors, studies have also shown that the extracellular matrix (ECM) that surrounds SMC 
in the vessel wall can impart control over SM phenotypes (114).  Indeed, genetic ablation 
of either fibronectin or the 5 integrin fibronectin receptor results in embryonic lethality 
associated with impaired SMC investment of both embryonic and extraembryonic vessels 
(115, 116).  Although the precise signaling mechanisms by which these diverse agonists 
and ECM regulate SMC transcription have not been completely delineated, several 
studies indicate that many (but not all) SM-specific genes (particularly contractile genes) 
depend on the presence of an serum response factor (SRF) DNA binding element termed 
a CArG box (CC(A/T)6GG) and many of these aforementioned intrinsic factors alter SRF 
or SRF-cofactor activity (58, 117-120).  
 One of the major proteins involved in the integrin intracellular signaling cascade 
is the non-receptor protein tyrosine kinase, focal adhesion kinase (FAK), which is 
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strongly and rapidly activated by various aforementioned growth factors and by ligation 
of all 1, 3 or 5 containing integrins (121).  Although a direct role for FAK in vascular 
growth and development has yet to be examined, germline deletion of FAK phenocopies 
the lethal defects observed in fibronectin-/- and 5 integrin-/- embryos. Interestingly, our 
lab recently showed that FAK activity is regulated in a unique fashion in SMC, whereby 
a separate protein comprising the carboxyterminus of FAK, termed FRNK (FAK Related 
Non Kinase) that acts as a dominant-interfering mutant for FAK is selectively expressed 
in SMC with very high levels found in the large arterioles.  FRNK transcription results 
from the utilization of an alternative start site within the FAK gene and FRNK expression 
is independently regulated by a distinct promoter embedded within FAK intronic 
sequences (122, 123).  Whereas FAK protein levels remain relatively constant during 
vascular development, FRNK protein levels are dynamically increased in neonatal 
vessels and in adult vessels two weeks following injury, when SMC are transitioning 
from a synthetic to contractile phenotype.  
The aim of this study was to determine whether FRNK expression plays a direct 
role in the phenotypic modulation of SMC in vivo.  Herein we present evidence that 
FRNK-/- mice exhibit repressed SM marker gene expression during post-natal vessel 
growth and following vascular injury.  These data highlight the possibility that extrinsic 
signals regulate the SMC gene profile by modulating the dynamic expression of FRNK. 
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MATERIALS AND METHODS 
 
Generation of Mice 
Mice with germline deletion of FRNK were generated by homologous 
recombination as previously reported and were backcrossed to the C57/Bl6 strain at least 
6 times before experimentation (124).  Animal procedures were approved by our 
accredited American Association for Accreditation of Laboratory Animal Care 
committee.   
 
Cell Culture, Transfections, and Reporter Assays 
 Aortic vascular smooth muscle cells (SMC) were cultured from mice or rats using 
enzymatic digestion as previously described (125).  Cells were maintained in Delbucco’s 
modified eagle medium with F12 supplemented with 10% fetal bovine serum and 0.5% 
penicillin/streptomycin and used from passage 8-16.  10T1/2 cells were obtained through 
ATCC and were maintained in Delbucco’s modified eagle medium supplemented as 
above.  Chick proepicardial cells were a generous gift from Mark Majesky.  Cells were 
induced to differentiate into coronary SMC (cSMC) by serum-starvation for 7 days as 
previously described (126).  For reporter assays, cells were transfected with appropriate 
constructs using TransIT-LT1 transfection reagent (Mirus) according to the 
manufacturer’s instructions.  Following transfections, cells were lysed in Glo Lysis 
Buffer and assayed using Steady Glo Luciferase Assay system (Promega) as directed by 
the manufacturer.  To determine FRNK half-life, SMC were treated with cyclohexamide 
(Sigma) for indicated times. 
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Immunocytochemistry and detection of BrdU incorporation in cultured cells 
Cells were processed for immunocytochemistry using previously published 
methods (122) In brief, cells were fixed with 4% paraformaldehyde, permeabilized with 
4% Triton X-100 in PBS, incubated with SM -actin (1:100)  for two hours.  After 
washing with PBS, slides were incubated for 1 hour with FITC-conjugated donkey anti-
mouse antibodies (2 g/ml) or Texas Red-conjugated phalloidin to detect filamentous 
actin. 
To measure proliferating cells, BrdU (Sigma, 30 g/mL) was administered to 
SMC grown on chamber slides.  After 4 hrs, cells were fixed in 4% paraformaldehyde 
and stained using a BrdU detection kit (Invitrogen). 
 
Transwell Assays 
 SMC were trypsinized and resuspended in DMEM:F12 containing 1% 
penicillin/streptomycin and 0.1% bovine serum albumin.  Approximately 15,000 cells 
were plated on transwell filters (8 µm pore size) precoated with FN.  After 18 hours, the 
cells were fixed in 4% paraformaldyhyde and the remaining cells in the upper chamber 
were removed with a cotton swab.  Migrated cells were stained with crystal violet and 
counted. 
 
Western Analysis 
To examine protein levels, lysates from cells or tissues were prepared by lysing in 
RIPA buffer with protease and phosphatase inhibitors as previously described (78).  
Protein concentration was determined by using a colorimetric BCA assay (Pierce).   
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Lysates were electrophoresed on an 11% polyacrylamide gel, transferred to 
nitrocellulose, and immunoblotted with antibodies for c-terminal FAK (Upstate), SM -
actin (Sigma), FAK pY397 (BioSource), SM-myosin heavy chain (generated by U. 
Groeschel-Stewart), and SM-22 (generous gift from Mario Gimona). 
 
Real-Time Quantitative RT-PCR 
 Tissue or cells were lysed in TRIzol (Invitrogen) and total RNA was isolated 
accoroding to the manufacturer’s protocol.  Expression was measured using the ABI 
Prism 7700 TaqMan system.  Primers and fluorescent probes were designed for the 
following genes: FRNK (Forward: GCTGCATTCTGAGGCGTTTA, Reverse: 
CAGGATTGTGCACCACCAG, Probe: AGCCAGGACTGAGACGCCGCC), FAK 
(Forward: GAAAGCAGTAGTGAGCCAACC, Reverse: 
GAGACTGTCCACTATCTTCTG, Probe: CTCCATGCCTGATAATACTGGCCCAG), 
SM-22 (Forward: TGCAGTGTGGCCCTGATGT, Reverse: 
TGCTCAGAATCACGCCATTCT, Probe: AGATCGTGGGCGCCTGGGCT), and SM 
-actin (Forward: CGCTGTCAGGAACCCTGAGA, Reverse: 
CGAAGCCGGCCTTACAGAG, Probe: CAGCACAGCCCTGGTGTGCGAC).  18S 
primers and probes were a generous gift from Hyung-Suk Kim.  Primers and probes for 
smoothelin were used as described previously (127). 
 
Animal Procedures 
 Genotypes were obtained from tail snip DNA using PCR analysis for primers 
specific to FRNK (124).   
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Conscious blood pressure was measured in mice aged 13 weeks using a tail cuff 
detection system (Hatteras).  Over a period of 20 minutes, 20 measurements were taken 
every day for 6 consecutive days.  Data is presented as an average of measurements for 
all days. 
 To measure unconscious blood pressure, mice were anaesthetized with 
isofluorane, and the left carotid artery was exposed.  A pressure transducer (Millar) was 
inserted through the carotid into the aorta to measure aortic pressure.  Phenylephrine was 
administered through a catheter inserted into the jugular vein.  Between doses of 
phenylephrine, each animal was allowed to recover its blood pressure to resting levels. 
 For injury studies, mice aged 9-10 weeks were anesthetized using isofluorane and 
a suture was tied around the left common carotid artery just below the bifurcation as 
previously described (41).  Animals were allowed to recover and were sacrificed at 
various times following injury.  For RNA studies, a 3mm portion of the carotid was 
dissected out from 1 mm below the site of ligation (left), or 1mm below the bifurcation 
(right).  For histology, the carotids were removed en bloc and sectioned serially from 2-3 
mm away from the site of injury.   
 
In situ hybridization 
Tissues from 1 week post-natal C57black6 mice were harvested, fixed and 
embedded in paraffin.   Serial sections (12 m) were hybridized in the absence or 
presence of a FRNK-specific digoxingenin-labeled antisense RNA probe O/N at 42o C.  
Sections were washed and incubated with an alkaline phosphatase-conjugated anti-
 58
digoxigenin antibody (Roche; 1:1,000 O/N at 4oC).   Slides were developed using 
NBT/BCIP as substrates (purple staining) and counterstained with methylene-green (1%).   
 
BrdU incorporation, Immunohistochemistry and Trichrome/Elastin Stain 
 Pregnant mothers were injected with BrdU (30 mg/kg) 1 day prior to giving birth.  
Wild type (+/+) or FRNK-/- (-/-) pups were sacrificed at postnatal day 4 and aortas were 
removed, paraffin embedded, and sectioned.  An antibody to BrdU was used to detect 
proliferating cells within the media. Positively stained area was quantified with ImageJ 
software.   
For general tissue immunohistochemistry, tissue from mouse pups or post-
surgical animals was harvested, formalin-fixed, and paraffin-embedded.  Sections (8-9 
m) were dehydrated, permeabilized, blocked, and incubated with an antibody for SM -
actin (Sigma).  Antibody binding was detected with HRP-linked secondary antibody.  
Sections were developed with diamino benzidine and subsequently counterstained with 
methyl green.  For morphometric measurements, a modified Masson’s 
trichrome/Verhoeff stain was used to localize elastin.  We used ImageJ (NIH) to measure 
circumference of the lumen, internal elastic lamina (IEL), and external elastic lamina 
(EEL), along with area of the media and lumen. 
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RESULTS 
 
 The 41/43 kDa FRNK protein is selectively expressed in the vasculature from 
approximately E12.5 onward with highest levels observed in large arterioles and lung of 
neonatal rats (post-natal day 4-14)  (Figure 3.1A) (93, 124).   As previously reported (and 
depicted in Figure 3.1B), FRNK expression is regulated by a promoter embedded within 
the fak gene and frnk transcription initiates from a non-coding exon located 
approximately 300 bp upstream of the FRNK translational start site in the mouse gene. 
(93, 123).    Since FRNK shares the same amino acid sequence as the C-terminus of 
FAK, we have been unable to develop a specific antibody that recognizes FRNK (but not 
FAK) for immunohistochemical analysis of FRNK expression patterns. However, since 
the frnk non-coding exon is selectively protected in RNA isolated from SMC and SMC-
containing tissues (93), we developed an in situ probe directed against this unique 
sequence to examine FRNK expression patterns in vivo.   Our in situ analysis of tissues 
harvested from post-natal day 7 mice revealed that FRNK is expressed throughout the 
media of large arterial vessels, but is not expressed in either the endothelium or 
adventitial layer (Figure 3.1C, top).  Some visceral SMC staining was apparent as well, 
with high levels observed in the lung (Figure 3.1C) and bladder (not shown).  FRNK 
expression in the lung was localized to the smooth muscle lining of the bronchi in 
addition to vessels (Figure 3.1C, middle and bottom left), similar to the staining pattern 
observed for SM-actin (Figure 3.1C, middle and bottom right).  FRNK was also 
detectible (albeit in low levels) in coronary arteries (data not shown) and coronary SMC 
cultures derived from explanted pro-epicardial organs (Figure 3.1D) (126).  Further 
analysis of FRNK expression in the developing mouse vasculature using quantitative RT-
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PCR revealed a dynamic up-regulation of FRNK mRNA in aorta between 7 and 10 days 
post-natal, corroborating our previous Western analysis (Figure 3.1E).  Since our 
previous studies revealed that ectopic expression of FRNK attenuated FAK activity and 
blunted PDGF-stimulated growth and motility of SMC, we theorized that FRNK might 
function to regulate SMC phenotype in post-natal vessels.  FRNK-/- mice were recently 
generated by a strategy that resulted in deletion of a 1kb fragment that included the non-
coding exon and 700 bp of upstream fak intronic sequence (see schematic in Figure 
3.1B).  Although these mice were born in the expected Mendelian frequency and showed 
no gross phenotype, they were not specifically examined for defects in SMC 
differentiation marker gene expression or growth (124).  Since the timing of FRNK 
expression during development and following vascular injury correlates with the 
conversion of SMC from a synthetic to contractile phenotype, we first examined the 
proliferation index of medial SMC in post-natal vessels from wild type or FRNK-/- mice. 
As shown in Figure 3.2A, medial SMC in post-natal FRNK-/- vessels exhibit a 
significantly higher index of BrdU incorporation in comparison to littermate control 
vessels.  Importantly, SMC tissue from postnatal FRNK-/- pups reveal lack of FRNK 
protein and higher levels of active pY397FAK, in comparison to wild type littermate 
controls, while total FAK protein levels are unaltered (Figure 3.2B).   
 We next analyzed the dynamic expression of the contractile genes, SM-actin, SM-
22, and smoothelin in the aorta of post-natal control and FRNK-/- mice by quantitative 
RT-PCR.  Expression of these contractile genes is enhanced approximately 6-10 fold 
from 4 day post-natal to adult vessels in wild type mice (data not shown).  However, as 
shown in Figure 3.2C, FRNK-/- vessels contain significantly fewer transcripts of these 
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genes in the 2-3 week period of vessel development, when FRNK protein is most highly 
abundant in wild type vessels (93).   
  Since the depletion of FRNK from developing vessels appeared to prolong the 
synthetic phenotype of SMC in the developing vasculature, we reasoned that FRNK-/- 
mice might exhibit defective vascular homeostasis.  However, we found that FRNK-/- 
mice did not exhibit significant changes in mean systolic blood pressure (as assessed by 
tail cuff measurements) or pressor responses (as assessed by intra-aortic catheterization) 
following phenylephrine treatment in comparison to wild type littermate controls (Figure 
3.3A, B).  In accordance with these data, medial thickness of FRNK-/- adult arterioles 
(aorta or carotids) was not significantly different from that of littermate control vessels, 
indicating that the lag in SM differentiation observed in the neonatal vessels was 
normalized during vessel maturation (Figure 3.3C).  Indeed, no significant differences in 
SM22, SM-actin or smoothelin expression were observed in adult aorta (see data for 8 
week animals in Figure 3.2C) or carotid vessels isolated from wild type or FRNK-/- mice 
(Figure 3.4A).   
 Since we previously reported that FRNK expression is relatively low in adult vessels, 
but is dramatically up-regulated by 14 days following catheter-induced vessel injury, we 
postulated that FRNK might also regulate SMC phenotypic switching during restenosis.  
Numerous studies have revealed that contractile gene expression is dynamically regulated 
during following vascular injury induced by either vessel ligation or surgical endothelial 
denudation.  Typically, reduced SMC marker gene expression is apparent within 3-7 days 
following injury followed by a burst of re-expression returning after approximately 2-3 
weeks following injury (40, 41).  To examine a possible involvement of FRNK in the 
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regulation of SMC re-differentiation following vascular injury, we performed quantitative 
RT-PCR for SM marker genes in wild type and FRNK-/- carotid arteries 7-21 days 
following carotid ligation.  As shown in Figure 3.4A-C, significant decreases in re-
expression of SM-actin, SM-22, and smoothelin (but not -actin) were observed in 
FRNK-/- vessels in comparison to littermate controls, indicating that the recovery of SM 
differentiation was defective in injured FRNK-/- arteries.  Notably, no significant 
differences in SM gene expression were observed in the control un-ligated right carotid 
artery at the time points examined (data not shown).  Concomitantly, 
immunohistochemical analysis for SM-actin revealed a striking difference between wild 
type and FRNK-/- vessels 14 days after ligation. While, robust SM-actin staining was 
observed throughout the media and neo-intima of wild type vessels, SM-actin 
expression in the neoinitma of FRNK-/- vessels was markedly reduced (Fig 3.4D).  While 
we anticipated that this phenotype might lead to a more exacerbated injury response, 
morphometric analysis at this time point revealed no significant differences in the extent 
of remodeling induced by ligation of wild type and FRNK-/- vessels, likely due to the fact 
that the ligation induces a very strong proliferative response in wild type C57Black6 mice 
(Figure 3.5).  Indeed, by 21 days after ligation full occlusion of injured vessels was 
observed in both wild type and FRNK-/- mice.  Collectively, these data provide strong 
support for the hypothesis that up-regulation of FRNK expression following vessel injury 
is required for appropriate SMC maturation that occurs subsequent to injury repair. 
The studies described above suggested a role for FRNK in promoting SMC 
differentiation.  To directly explore this possibility, we performed SMC promoter-
reporter assays in 10T1/2 cells, a multi-potential SMC precursor line that has been shown 
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to markedly up-regulate SMC-specific gene expression upon stimulation with serum, 
S1P, or TGF- (57, 128).  While FRNK is not expressed in detectible levels in 10T1/2, 
forced expression of FRNK in these cells inhibited FAK activity and resulted in a two to 
four-fold increase in SM22, SM-actin and SM-MHC promoter activity (Fig 3.6A). We 
reasoned that FRNK expression likely promotes SMC differentiation by relieving FAK-
dependent repressive signals.  To determine whether FAK activation limits SM marker 
gene expression we ectopically expressed a constitutively active FAK variant (termed 
SuperFAK (129)) that leads to enhanced FAK activity as assessed by phosphorylated 
Y397FAK levels. As shown in Figure 3.6B, SuperFAK expression in 10T1/2 cells 
significantly reduced SM22 and SM-actin reporter gene expression (Fig 3.6B).  
Similarly, ectopic expression of FRNK and FAK variants in primary rat aortic SMC 
revealed an inverse relationship between FAK activity and SM gene expression (i.e. low 
FAK activity correlates with high levels of SM markers, Fig 3.6C).  Notably, aortic SMC 
isolates from FRNK-/- mice consistently exhibited enhanced FAKpTyr, and lower levels 
of the contractile proteins SM22, SM-actin, and SM-MHC than SMC isolates from aged 
matched (and passage-matched) control mice (Fig 3.6D). Expression of FRNK does not 
effect transcription of myocardin (Figure 3.6E).  Staining FRNK-/- SMC revealed that 
deletion of FRNK results in lower, yet detectable levels of SM a-actin expression (Figure 
3.7A).  Re-expression of FRNK also decreased proliferation and migration of FRNK-/- 
SMC (Figure 3.7A, B).  Taken together, our findings provide compelling evidence that 
FAK activity limits SMC differentiation, and up-regulation of FRNK promotes 
differentiation by attenuating FAK activity. 
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We next sought to identify factors that can modulate dynamic FRNK expression 
during vascular morphogenesis.  We first utilized a FRNK promoter reporter construct to 
define factors that regulate FRNK transcription.  A fragment comprising approximately 
6kb of sequence upstream of the FRNK ATG (-5388 to +876) was previously shown to 
drive SM-specific expression of LacZ in vivo in a pattern reminiscent of FRNK 
expression (124).  As shown in Figure 3.8A, we found that the corresponding FRNK 
promoter attached to a luciferase reporter (FRNK-Luc) exhibited high activity in cultured 
SMC in comparison to 10T1/2 cells (consistent with the levels of FRNK expressed in 
these two cell types).  Although FRNK is expressed in a SM-restricted fashion, careful 
analysis of the FRNK promoter region from chicken, mouse and human sequence did not 
reveal any conserved CArG elements, known to direct SRF-dependent transcription.  
Indeed, co-expression of SRF and FRNK-Luc in SRF-/- ES cells did not alter basal 
FRNK-Luc promoter activity in these cells, while expression of a SM-actin-Luc 
construct was induced approximately 15-fold (Figure 3.8B). Furthermore, when 
expressed in SMC, the FRNK-Luc construct was un-responsive to over-expression of the 
myocardin family of SRF co-factors, which stimulated strong activation of the SM-
actin-Luc reporter (Figure 3.8C).  Endogenous FRNK transcription was not stimulated by 
overexpression of Flag-Myocardin, whereas SM-22 expression was increased 
approximately 75-fold (Figure 3.8D).  Collectively, these data provide strong support for 
FRNK being expressed in a non-SRF/CARG dependent fashion as previously suggested 
(104). 
We next screened a number of cytokines/growth factors known to be released 
following vessel injury for their ability to increase FRNK promoter and protein levels in 
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cultured rat aortic SMC.  We found that TGF- induced a marked increase in FRNK-Luc 
activity, FRNK mRNA (as assessed by quantitative RT-PCR) and protein levels 
compared to vehicle treated cells (Figure 3.9A-C), while other agonists including the 
potent SMC mitogens PDGF-BB, S1P, angiotensin II, thrombin, and basic-fibroblast 
growth factor had no effect (data not shown).   Since TGF- induces SM differentiation, 
we wondered whether FRNK expression might contribute to the TGF- response.  To this 
end, we next examined TGF- stimulated SM gene expression in our cell culture models.  
We found that TGF- induced a more robust induction of SM22 reporter activity in 
FRNK expressing compared to vector-transfected control 10T1/2 cells (Figure 3.9D).  In 
addition, we found that TGF--induced expression of endogenous SM22 was 
significantly decreased in FRNK-/- SMC in comparison to matched wild type SMC 
isolates (Figure 3.9E).  Collectively, these data provide support for a model whereby 
TGF- induces FRNK expression and that FRNK, in turn, contributes to TGF- induced 
SMC differentiation by dampening FAK-dependent signals.   
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DISCUSSION 
 
FRNK, a dominant interfering mutant that attenuates FAK activity, exhibits 
selective and dynamic expression in SMC. We previously reported that FRNK attenuates 
SMC proliferation and migration by regulating FAK/Rac1-dependent signaling (78).  
Herein we have found an additional function for FAK/FRNK signaling in SMC.  We 
present evidence that FRNK deletion (by homologous recombination) represses SM gene 
expression during post-natal vessel growth and following vascular injury.  We also show 
that FRNK expression is regulated by TGF- and that forced expression of FRNK 
induces SM marker gene expression in cultured cells grown in serum and enhances TGF-
-stimulated SM marker gene expression.  Conversely, FRNK deletion or expression of a 
constitutively activated FAK variant attenuated SM gene transcription.  These data 
suggest that enhanced FAK activity is permissive for SMC growth and migration, but 
limits SM differentiation, and that tight regulation of FAK activity is likely important for 
proper SMC phenotypic modulation during development and following vascular injury. 
FAK is activated by a process that involves dimerization and intermolecular 
phosphorylation of tyrosine 397 in trans (130).  Phosphorylation of Y397 results in 
subsequent recruitment of the tyrosine kinase Src (and/or Fyn), which phosphorylates and 
further activates FAK (and phosphorylates certain FAK binding partners) (82).  FRNK 
likely attenuates FAK activity by inducing the formation of FRNK/FAK heterodimers 
that are incapable of Y397 phosphorylation and Src binding.  In support of this notion, 
expression of wild type FAK (and Src) can rescue FRNK-dependent inhibition of FAK 
(and paxillin) phosphorylation, while expression of a phospho-deficient FAKY397F 
cannot (131).  Our findings indicating that FAK activity is enhanced in tissues and cells 
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derived from FRNK-/- mice strongly support the hypothesis that the dynamic regulation 
of FRNK expression can impart specific spatial and temporal control of FAK activity in 
vivo.  In this regard, it is interesting to note that FAK protein is extremely stable with a 
reported half-life exceeding 20 hr (132), while FRNK protein turnover is rapid (Figure 
3.1F).  We speculate that transient FRNK expression is particularly important in the 
vasculature, where direct apposition of SMC with extracellular matrix could lead to high 
levels of FAK activation and un-controlled SM growth.  It is feasible, however, that 
FRNK has additional FAK-independent functions, and future studies will examine this 
possibility.  
In support of the idea that FRNK/FAK signaling plays an active role in regulating 
smooth muscle cell phenotypes, FAK-/- mouse embryonic fibroblasts were recently 
reported to exhibit a myo-fibroblast appearance as assessed by high levels of SM -actin 
containing stress fibers relative to control fibroblasts (133).  Interestingly, we recently 
found that FAK-deficient SMC (like FRNK over-expressing SMC) exhibit enhanced 
TGF- stimulated SM marker gene expression (un-published observations).  In addition, 
recent studies have provided evidence for a role of FAK in promoting striated muscle cell 
differentiation as the dynamic regulation of FAK activity was found to be essential for 
differentiation of C2C12 myoblasts into myotubes (134).  Also, a role for FAK in the 
promotion of cardiogenesis was suggested by studies in which stable expression of 
FRNK in ES cells was shown to induce cardiac -myosin heavy chain and sarcomeric 
myosin expression (135). Since SRF plays a critical role in the regulation of contractile 
gene expression in each of these muscle types, it will be of future interest to determine 
whether limiting FAK activity regulates SRF activity and/or co-factor recruitment.   
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 Since FRNK exhibited a striking SMC-restricted expression pattern, we sought to 
explore the mechanisms underlying its transcriptional regulation.  Interestingly, we found 
that the FRNK promoter does not contain a canonical CArG box, is not affected by SRF 
deletion, and is un-responsive to over-expression of the myocardin family of potent SRF 
co-factors.  Thus, FRNK belongs to a sub-class of smooth muscle specific genes that are 
regulated in a CArG-independent fashion including aortic carboxypeptidase-like protein 
(ACLP), cysteine-rich protein 2 (CRP2), and histidine-rich calcium-binding protein 
(HRCBP) (100, 101, 103).  Interestingly, TGF-, a strong activator of SMC 
differentiation, led to significant up-regulation of FRNK expression.  Thus, future 
exploration of the TGF--dependent mechanisms that control FRNK expression may lead 
to identification of additional transcription factors that regulate SMC phenotypes. 
Although reported to affect a wide variety of cellular processes a principal 
function for FAK in numerous cell types is its ability to modulate integrin and growth 
factor receptor-stimulated cellular migration (82).  Direct evidence for the role of FAK in 
modulating fibronectin-dependent motility was previously shown using FAK-/- 
fibroblasts, endothelial cells, neurons, and keratinocytes (136-139).  We previously 
showed that FRNK expression in SMC attenuated FAK-dependent PDGF-stimulated 
chemotaxis (93) and our recent studies reveal that FAK-/- SMC exhibit a similar defect 
(un-published observations).  Since FRNK appears to play a dual role in SM function; 
aiding to block SMC growth and migration and to promote SMC differentiation, FRNK 
may function as a toggle in the regulation of SMC phenotypes. 
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Figure 3.1.  FRNK is expressed selectively in smooth muscle containing-tissues.  A. 
Immunoblot showing expression of FAK and FRNK in tissues from 14d postnatal rat.  B. 
Schematic of FAK and FRNK cDNA and genomic locus.  Shaded areas represent FAK-
specific (blue), FRNK-specific (green), or common (red) coding regions.  C. In situ 
hybridization in postnatal day 7 mouse aorta and lung using sense and anti-sense probes 
directed against the FRNK non-coding exon.  Immunohistochemistry for SM-actin is shown 
as a positive control.  D.  Western blot of FRNK and FAK levels in coronary SMC (cSMC), 
and bovine endothelial cells (BEC). E.  Quantitative RT-PCR of FRNK message levels in 
thoracic aorta was dissected from mouse pups 1, 4, 7, 10, and 14d post-natal.  Data is 
normalized to expression of 18S and expressed as the mean +/- SEM (n > 4 for each 
timepoint, * p < 0.01, # p < 0.05).   
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Figure 3.2.  FRNK-/- mice exhibit increased SM proliferation and attenuated expression 
of SM marker genes during development.  A. BrdU incorporation in post-natal day 4 
thoracic aorta collected from wild type (+/+) or FRNK-/- (-/-) mice.  Data is expressed as the 
mean +/- SEM (n=5, p<0.03).  B. Western analysis in post-natal day 4 bladders from 
heterozygous (+/-) or FRNK-/- (-/-) pups. pY397 reveals enhanced active FAK in -/- tissue.  C. 
Quantitative RT-PCR for indicated SM differentiation markers in +/+ and -/- thoracic aorta 
collected from 4 days to 8 weeks post-natal.  Data is normalized to expression of 18S and is 
expressed as the mean percent of wild type expression at each time point +/- SEM (n > 4 for 
each timepoint, ** p < 0.01, * p < 0.05).   
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Figure 3.3.   FRNK-/- mice do not display abnormal homeostasis.  A. Wt (+/+) and FRNK-/- 
(-/-) mice aged 13 weeks were subjected to tail cuff measurement of systolic blood pressure.  
Data is presented as an average of the calculated mean for each mouse over 6 days, +/- SEM.  
B. Blood pressure was measured in anaesthetized mice aged 14 weeks by aortic 
catheterization during administration of phenylephrine (PE) into the jugular vein. Data are 
expressed as the mean +/- SEM.  C. Aortic medial thickness was measured using ImageJ 
software in Wt (+/+) and FRNK-/- (-/-) mice aged 13 wks from formalin-fixed, paraffin-
embedded sections stained with SM -actin.  Data is expressed as the mean +/- SEM.  Sample 
histology with staining for SM -actin from mice aged 13 weeks is shown at right.   
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Figure 3.4.  FRNK-/- mice show decreased expression of SM marker genes following 
carotid artery ligation.  Wild type (+/+) or FRNK-/- (-/-) mice were subjected to left carotid 
blood flow cessation as described in the Methods section.  A-C.  Total RNA was extracted 
from the left and right carotids pre- and post-ligation and processed for real-time quantitative 
RT-PCR for the indicated SM markers and -actin (control).  Data is presented as the left 
carotid normalized to expression in the wild type right (control) carotid artery at each 
timepoint +/- SEM (n >4, * p<0.01, # p<0.05).  D.   Verhoeff’s elastin and 
immunohistochemistry for SM -actin staining in the right and left carotid arteries removed 
from wild type (+/+) or FRNK-/- (-/-) mice 14 days following ligation. Black bars indicate 
thickness of neointima. 
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Figure 3.5.  FRNK-/- mice show no differences in vessel growth in response to carotid 
artery ligation.  Wild type (+/+) and FRNK-/- (-/-) mice were subjected to ligation of the left 
carotid artery for 14 days.  Measurements were taken from trichrome/elastin stained sections 
using ImageJ (NIH).  A. The distance between the IEL and EEL in the right and left carotid 
was measured at 9 points along the 3mm region of remodeled vessel for each individual 
animal.  Data is presented as the average of the mean for each animal, +/- SEM.  B. The 
circumference of the lumen, IEL, and EEL was measured three times from the left carotid of 
each animal.  C. Ratio of intimal area:medial area in the left, injured carotid.  Data for each 
panel is presented as the average of the mean for each animal, +/- SEM.    
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Figure 3.6. SM marker gene expression is induced by FRNK expression.  A. 10T1/2 cells 
were transfected with SM-MHC, SM -actin, or SM22 luciferase reporter plasmids.  24 hours 
later cells were infected with either GFP or GFP-FRNK adenovirus for an additional 24 hours 
prior to luciferase detection. Bottom right: Western analysis of 10T1/2, SMC or 10T1/2 
infected with GFP or GFP-FRNK adenovirus as described above.  B. (Left) 10T1/2 cells were 
co-transfected with SM22 or SM -actin luciferase and empty vector or SuperFAK and 
reporter assays were performed as described above.  (Right) Western analysis of 10T1/2 cells 
transfected with Flag vector (C), Flag-FAK, or Flag-SuperFAK (SFAK).  C. Rat aortic SMC 
were co-transfected with SM22-luciferase reporter construct and with either empty vector (C), 
SFAK, FAK, Y397FFAK or FRNK in the presence of serum.  (Left) Luciferase activity was 
measured 48 hrs following transfection.  (Right) Western analysis shows activation state of 
FAK using phospho-specific FAK pY397 antibody and expression of Flag-tagged constructs 
with Flag antibody.  D. Western analysis of primary cell isolates generated from pools of 
thoracic aortas harvested from 6 week post-natal wild type (+/+) or FRNK-/- (-/-) mice.  
Cultured cell data are representative of three separate isolates of wild type and FRNK-/- 
collected at identical passage numbers.  E.  Rat Aortic SMC were infected with GFP or GFP-
FRNK as described above.  Total RNA was collected and RT-PCR was used to measure 
myocardin expression.  Promoter data are expressed as mean +/- SEM for at least 3 separate 
experiments.  Western analyses are representative of at least 3 experiments.   
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Figure 3.7.  Re-expression of FRNK attenuates serum-dependent growth and migration 
in FRNK-/- cells.  A. FRNK-/- (-/-)or WT (+/+) cells were maintained in serum, fixed in 4% 
paraformaldyhyde, and stained with an antibody for SM -actin and phalloidin.  The top two 
left pictures were taken at the same level of exposure, and the bottom picture is a longer 
exposure to differences in SM a-actin expression.  B. FRNK-/- cells were infected with GFP or 
GFP-FRNK adenovirus for 24 hours.  The next day, cells were treated with BrdU (30 ug/mL) 
for 4 hours.  After fixation, cells were stained with an antibody for BrdU and positive cells 
were counted.  C. Cells were infected as described above for 24 hours and subsequently plated 
onto transwell filters (see materials and methods).  After 18 hours, migrated cells were 
counted. 
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Figure 3.8.  Activity of the FRNK promoter is regulated in a SM-specific but CArG-
independent fashion.  A. 10T1/2 or VSMC were transfected with 6kb FRNK-Luc or TK-Luc 
and assayed for luciferase activity 48 hours later.  B. SRF-/- ES cells were co-transfected with 
either FRNK-Luc or SM -actin-Luc in the presence of empty vector or SRF and processed 
for luciferase activity at 24 hr.  C. Rat aortic SMC were transfected with FRNK-luc or 
SMactin-luc in the presence of empty vector, myocardin, or MRTF-A and were processed 
for luciferase activity at 48 hr.  D. 10T1/2 cells were transfected with Flag or Flag-Myocardin.  
Total RNA was collected and RT-PCR was performed to measure levels of FRNK.  Data from 
reporter assays is normalized to TK promoter activity in the presence of empty vector for each 
reporter.  RT data is normalized to 18S. All data are presented as the mean +/- SEM of 3-5 
experiments. 
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Figure 3.9.  TGF- treatment increases levels of FRNK expression.  A. 10T1/2 cells were 
transfected with FRNK-Luc in serum-containing media.  24 hours later, media was replaced 
with serum-free media and cells were dosed with vehicle or TGF-β (1 ng/mL) for an 
additional 24 hr at which time cells were assayed for luciferase activity.  The data are 
expressed as the mean +/- SEM (n=3, p<0.01).  B. Quantitative RT-PCR for FRNK was 
performed on RNA isolated from SMC grown in serum-free media and treated with 1 ng/mL 
TGF-β or vehicle for 18 hr.  Data are presented as fold increase in FRNK expression relative 
to untreated cells and is expressed as the mean +/- SEM (n=3, p<0.01).  C. Western analysis 
for FRNK and FAK in serum-starved SMC treated with vehicle or TGF-β (1 ng/mL) for 24 
hrs  D. 10T1/2 cells were transfected with SM22-luc and infected with GFP or GFP-FRNK 
adenovirus 24 hours later.  Cells were serum starved and treated with TGF- as described 
above and processed for luciferase activity 24 hr later.  E. Quantitative RT-PCR for SM-22 
message in wild type (+/+) or FRNK-/- (-/-) cells serum starved and treated with TGF- as 
described above for 24 hr.  Data is normalized to presence of 18S and is expressed as the mean 
+/- SEM (n=3, *p<0.05).   
 
 
 
 
CHAPTER IV 
 
CARDIAC NEURAL CREST-SPECIFIC INACTIVATION OF FOCAL ADHESION KINASE LEADS TO 
OUTFLOW TRACT DEFECTS ASSOCIATED WITH ENHANCED SMOOTH MUSCLE CELL 
MATURATION AND IMPAIRED MOTILITY2,3  
                                                 
2 Work submitted to Jounral of Biological Chemistry in June 2008 as: Rebecca L. Sayers*, Liisa J. 
Sundberg-Smith*, Lee E. Mangiante, Hilary E. Beggs, Louis F. Reichardt, Robert J. Schwartz, Christopher 
P. Mack, and Joan M. Taylor.  Cardiac neural crest-specific inactivation of focal adhesion kinase leads to 
outflow tract defects associated with enhanced smooth muscle cell maturation and impaired motility.  
(*These two authors made equal contributions to this work.) 
 
3 Portions of this work, including Figures 4.4, 4.5, 4.7, and 4.8A, were included in the dissertation of Liisa 
Sundberg Smith as: Smith, Liisa Sundberg.  A role for focal adhesion kinase in vascular smooth muscle cell 
proliferation, migration and differentiation.  The University of North Carolina at Chapel Hill, 2007, 2036 
pages; AAT 3272708 
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ABSTRACT 
 
Focal Adhesion Kinase (FAK) is strongly activated by integrin/matrix interactions 
and growth factor receptor engagement, and the observation that fak-/- mice die between 
E8.5-10 with notable defects in vessel integrity suggests that FAK may play an important 
role in vascular maturation.  In the current study we demonstrated that conditional 
deletion of FAK in wnt-1- or nkx2-5-expressing cells led to persistent truncus arteriosus 
that was incompatible with post-natal life.  Given that aorticopulmonary septation 
involves the precise spatial and temporal coordination of several smooth muscle cell 
(SMC) processes including migration, proliferation, differentiation, and apoptosis, these 
studies suggest that FAK plays a critical role in SMC development.  Indeed, our studies 
in FAK null aortic SMC cultures revealed a dual function for FAK in regulating SMC 
phenotype. FAK inactivation did not influence cell growth or survival, but markedly 
attenuated serum- and PDGF-BB-dependent chemotaxis.  In addition, FAK inactivation 
also promoted serum- and TGF--stimulated SMC differentiation marker gene 
expression, which was mediated at least in part, by p38 Map Kinase.  To our knowledge 
these studies are the first to define a cell autonomous role for FAK in the developing 
outflow tract and our results provide interesting new insights into the mechanisms 
underlying some of the most common congenital defects in humans including Tetralogy 
of Fallot and the DiGeorge Syndrome.   
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INTRODUCTION 
 
The investment of newly formed endothelial cell tubes with differentiated smooth 
muscle cells (SMC) is a very important process during vessel formation and requires 
intricate regulation of SMC motility, growth, and differentiation.  Mature medial SMC 
express high levels of contractile genes (i.e. myosin heavy chain (SM-MHC), SM -
actin, SM22 among others) and their presence is essential for maintaining vessel tone 
and for providing dynamic control of blood pressure (see (47) for review).   Although 
there is no master regulator of SMC specification, serum response factor (SRF) binding 
to conserved CArG (CC(A/T)6GG) promoter elements is required for the expression of 
most SMC differentiation marker genes and it is well known that SRF activity is 
regulated through interactions with additional cell-type-selective and ubiquitous 
transcription factors.  The potent SRF co-factors of the myocardin family (myocardin and 
myocardin-related transcription factors, MRTF-A and B) are particularly strong 
activators of SMC-specific gene expression.  The importance for myocardin in SMC 
differentiation is underscored by the finding that germline deletion of myocardin leads to 
embryonic lethality by E9.5 accompanied by a near complete lack of SMC lining major 
vessels (140).  Extensive evidence indicates that extracellular matrix signaling is also an 
important regulator of SMC growth and differentiation as deletion of either fibronectin 
(FN), the 5 integrin FN receptor, or focal adhesion kinase (FAK) (the kinase that 
mediates 5-dependent signaling) each results in extraembryonic and embryonic vessel 
defects leading to lethality in the mouse from E8.5 to E10 (115, 116, 141).   
Although a direct role for FAK in vascular smooth muscle growth and 
development has yet to be examined, FAK is known to play critical role in matrix 
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signaling by supporting the formation of multi-protein signaling complexes that lead to 
downstream activation of a number of signaling molecules that have been previously 
implicated in the regulation of SMC phenotype including ERK, JNK, and the small 
GTPases, Rac and Rho (142).  Importantly, our lab recently showed that FAK activity is 
regulated by the SMC-specific expression of FRNK (FAK-Related Non Kinase), a 
carboxyterminal variant of FAK that acts as an endogenously expressed dominant 
negative.  While FAK protein levels remained relatively constant during vascular 
development, FRNK expression in SMC is significantly increased in the post-natal period 
and two to three weeks following vessel injury (122).  These results suggest that FAK 
activity is tightly controlled in SMC especially during the transition from the synthetic to 
contractile phenotype.  
It is clear that SMC play an important part in the intricate and complex series of 
events that must occur during the remodeling of the pharyngeal arches into an 
asymmetric aortic arch with appropriate division of the great vessels, but their precise 
functions are not yet known.  The cardiac outflow tract and pharyngeal arches contain 
SMC derived from two distinct embryological origins, the cardiac neural crest and the 
secondary heart field.  Elegant cell tracing studies in the chick and mouse have revealed 
that the tunica media at the base of the aorta and pulmonary trunk is invested by vascular 
smooth muscle derived from nkx2-5-expressing cells from the secondary heart field 
(143).  Additional studies revealed that the vascular smooth muscle layers in the aorta 
from the aortic root (just distal to the nkx2-5-derived field) to the point of insertion of the 
ductus arteriosis, as well as the SMC within the internal carotid and proximal subclavian 
arteries are derived from wnt-1-expressing cardiac neural crest (CNC) cells (12, 144, 
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145).  Interestingly, both wnt-1- and nkx2-5-expressing cells contribute to development of 
conotruncal septal SMC that divide the outflow tract into the aorta and pulmonary artery, 
allowing for dual systemic and pulmonary circulation (12, 145).   
It is becoming clear that mutations that regulate cardiac neural crest 
differentiation into SMC lead to outflow tract defects. Indeed, germline deletion of 
MRTF-B leads to embryonic lethality associated with impaired SMC differentiation and 
aberrant outflow tract (OFT) development, as does wnt-1 targeted deletion of myocardin 
(16, 17, 146).  In addition, TGF-, which promotes SMC differentiation (147-149), and 
PDGF-BB, which promotes SMC growth and motility, are important extrinsic regulators 
of SMC phenotype and genetic ablation of receptors for these genes also resulted in 
defective OFT morphogenesis (150, 151).  The identification of the signaling pathways 
linking these extrinsic factors to SRF activation will be very important for our 
understanding of the control of SMC phenotype during development and disease.   
The aim of the present study was to determine whether FAK activation plays a 
direct role in regulating SMC function during vascular development.  We present 
evidence that FAK deletion (by homologous recombination) in either wnt-1 or nkx2-5 
derived cells results in OFT development defects including persistent truncus arteriosis 
(PTA).  However these phenotypes were not accompanied by reduced SMC 
differentiation, instead our studies revealed that ablation of FAK enhanced TGF- 
stimulated SMC differentiation but attenuated PDGF-mediated SMC motility.  These 
studies are the first to define a cell autonomous role for FAK in SM development and 
they provide interesting new insights into mechanisms underlying some of the most 
common congenital defects in humans. 
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MATERIALS AND METHODS 
 
Generation of FAK-deficient mice 
 FAKnk mice: Mice homozygous for insertion of loxP sites flanking the kinase 
domain of FAK (fakflox/flox) (generated by Louis Reichardt and Hilary Beggs) were bred 
with nkx2-5Cre knock-in mice from Robert Schwartz (Institute of Biotechnology, 
Houston, TX) as previously described (152, 153).  Genetic controls are fakflox/flox nkx2-
5wt/wt and FAKnk mice are fakflox/flox nkx2-5wt/Cre. 
FAKwnt mice:  To generate fak+/- mice, fakflox/flox mice were bred with E2ACre 
mice to mediate germline Cre-mediated recombination of one floxed allele.  wnt-1Cre 
mice were obtained from Andrew McMahon (12) and crossed with fakflox/flox to obtain 
fakflox/+wnt-1Cre progeny.  After backcrossing to C57/Bl6 mice, resulting fak+/- mice were 
bred with fakflox/+wnt-1Cre mice to obtain fakflox/-wnt1Cre (FAKwnt) or fakflox/-wnt1 (genetic 
control) mice.  Genotypes were determined for all mice by obtaining DNA from tail snips 
and performing PCR.  All animal procedures were approved by the Institutional Animal 
Care and Use Committee. 
 
Antibodies and Reagents 
The Pyk2, phospho-specific ERK1/2, phospho-specific p38, and phospho-specific 
Smad 3 antibodies were purchased from Cell Signaling.   Anti-vinculin, SM-actin, and 
-tubulin antibodies were purchased from Sigma.  The N-term specific anti-FAK, C-term 
specific anti-FAK, phospho-specific Smad2, and anti-ERK2 antibodies were purchased 
from Upstate.  Paxillin antibody was purchased from BD Transduction Laboratories and 
anti-Cyclin D1 was purchased from Santa Cruz.  The anti-phospho Y397FAK antibody 
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was purchased from BioSource and the Texas-Red phalloidin was purchased from 
Molecular Probes.  SM-22 antibody was a generous gift from Mario Gimona and SM-
MHC antibody was obtained from U. Groeschel-Stewart.  PDGF-BB, TGF-and SB-
203580 were purchased from Calbiochem.  Ad5CMV Cre adenovirus was purchased 
from the University of Iowa Gene Transfer Vector Core and Ad5CMV LacZ adenovirus 
was purchased the University of North Carolina-Chapel Hill Viral Core.  Both viruses 
were expanded using Puresyn’s Adenopure adenovirus purification kit according to 
manufacturer’s protocol.   
 
Constructs 
The promoter reporter constructs: SM -actin (from -2560 to +2784), SM22 
(from -450 to +88) and SM-MHC (from -4200 to +11600) luciferase constructs used have 
been previously described (128).  6xSBE-luciferase was a gift from Li Li (Wayne State 
University) (119).  Flag-FAK was a generous gift from Dr. Tom Parsons (University of 
Virginia) and was previously described (154).  
 
Cell Culture and Agonist Treatment 
Aortic smooth muscle cells were isolated from either Wistar Rats or fakflox/flox 
mice.  In brief, thoracic aortas were stripped of the endothelial and adventitial layers by 
microdissection.  The SMC in the media were isolated by enzymatic digestion in buffer 
containing trypsin and collagenase as previously described (125).  Each of our 
preparations is routinely tested for expression of smooth muscle-specific markers (by 
immunohistochemistry) and the ability to drive SM-specific expression of reporter 
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constructs.  Only the cell lines that are deemed at least 85% pure by these measurements 
are utilized for further experimentation.  Cells are grown in DMEM: F12 (1:1) 
supplemented with 10% FBS and 1% penicillin-streptomycin and are used between 
passages 5 and 18.  10T1/2 cells (ATCC) were maintained in DMEM plus 10% fetal 
bovine serum and 1% penicillin-streptomycin.  
 
Cell Growth Assay 
 fakflox/flox SMC (pre-treated with CRE or Lac-Z adenovirus for 72 hr) were 
trypsinized and plated onto a 96-well microplate (5 x 103 cells/well).  Cells were serum 
starved for 24 hr and treated with PDGF-BB (20ng/ml) or EGF (100 ng/ml) for 48 hr.  
Cells were incubated with the formazen dye, WST-1 (10 l; Roche) for 4 hr and the 
absorbance was read at 450 nM as per manufacturers instructions.  Caspase activity was 
determined using the Caspase-Glo kit (Promega).  To measure proliferating cells, BrdU 
(Sigma, 30 g/mL) was administered to SMC grown on chamber slides.  After 4 hrs, 
cells were fixed in 4% paraformaldehyde and stained using a BrdU detection kit 
(Invitrogen). 
 
Transwell Assay 
SMC were trypsinized and resuspended in DMEM:F12 containing 1% 
penicillin/streptomycin and 0.1% bovine serum albumin.  Approximately 20,000 cells 
were plated on transwell filters (8 µm pore size) precoated with FN.  After 7 hours, the 
cells were fixed in 4% paraformaldyhyde and the remaining cells in the upper chamber 
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were removed with a cotton swab.  Migrated cells were stained with crystal violet and 
counted. 
 
Promoter Assays 
Cells were transfected using either Superfect (Qiagen) or Trans-IT (Mirus) 
transfection reagents according to the manufacturer’s protocol.  Luciferase activity was 
detected by the Steady-Glo luciferase assay reagent (Promega). 
 
RhoA Pulldown Assay 
Activity of RhoA was measured as previously described (128).  Briefly, cell 
lysates were incubated with 40 µg of a GST-rhotekin Rho binding domain fusion protein 
immobilized to glutathione-Sepharose 4B beads (Amersham Biosciences) for 45 min at 
4°C in binding buffer (50 mM Tris, pH 7.6, 500 mM NaCl, 0.1% SDS, 0.5% 
deoxycholate, 1% Triton X-100, 0.5 mM MgCl2). Beads were washed three times (50 
mM Tris, pH 7.6, 150 mM NaCl, 1% Triton X-100, 0.5 mM MgCl2) and resuspended in 
2x Laemmli buffer. Proteins were separated using SDS-PAGE, transferred to 0.2 µm 
polyvinylidene difluoride, and probed with anti-RhoA (26C4) (Santa Cruz 
Biotechnology). Loading controls (typically 10%) were taken from each lysate sample 
prior to pull downs. 
 
Western Blotting 
Western blots were performed using the appropriate antibodies at a 1/1000 
dilution.  Blots were washed in TBS-T (TBS plus 0.05% Triton-X), followed by 
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incubation with either horseradish peroxidase conjugated rabbit anti-mouse antibody or 
Protein A (Amersham) at a 1/2000 dilution.  Blots were visualized after incubation with 
chemiluminescence reagents (ECL, Amersham). 
 
Immunocytochemistry  
Cells were processed for immunocytochemistry using previously published 
methods (122) In brief, cells were fixed with 4% paraformaldehyde, permeabilized with 
4% Triton X-100 in PBS, incubated with specified primary antibodies for 1 hour at the 
following concentrations: anti-vinculin (1:1000) or anti-FAK (N-term 1:250).  After 
washing with PBS, slides were incubated for 1 hour with Texas Red-conjugated donkey 
anti-mouse antibodies (2 g/ml) or Texas Red-conjugated phalloidin to detect 
filamentous actin. 
 
Histology and Staining 
Pregnant females or postnatal pups were sacrificed at indicated times.  Whole 
embryos or neonatal heart and lungs were formalin-fixed, paraffin embedded, and 
sectioned to 8 m.  To examine morphology, sections were stained with hemotoxylin and 
eosin.  To detect expression of SM markers, immunohistochemistry was performed with 
antibodies to SM -actin and SM-22.  Briefly, sections were deparaffinized and 
rehydrated in graded ethanols.  For detection of SM-22, sections underwent citrate buffer 
antigen retrival (Vector).  All sections were treated with 0.23% hydrogen peroxide to 
block endogenous peroxidases and permeabilized in 0.4% TritonX-100.  Slides were 
blocked in 5% goat serum and incubated with primary antibody overnight.  For SM -
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actin, protein was detected using HRP linked anti-mouse secondary and 
diaminobenzioline.  For SM-22, biotinylated anti-rabbit secondary was used with the 
ABC detection kit (Vector). 
 
Statistics 
All results are representative of three independent experiments.  Data is presented 
as the mean +/- standard error of the mean (SEM).  Significance was determined using 
Student’s t test.   
 
 90
RESULTS 
 
To examine the role of FAK in SMC development, we utilized the wnt-1Cre line 
that induces recombination in a substantial portion of the proximal outflow tract SMC.  
These well characterized mice generated high efficiency recombination c.a. E9.5 in CNC-
derived SMCs populating pharyngeal arch arteries 3, 4, and 6 and the truncus arteriosis 
and by E11.5 they induced recombination within the SMC precursors invading the 
conotruncal cushions and the aorticopulmonary septum (12).    fakflox/flox mice were first 
interbred with wnt-1Cre  transgenics and the fak+/fl/wnt-1Cre offspring were subsequently 
crossed with mice heterozygous for the FAK allele (fak+/-).  At P0, we found the 
appropriate Mendelian distribution of fakflox/-wnt-1Cre/wt (herein referred to as FAKwnt) 
mice, however the FAKwnt mice died within the first two weeks of life (Table 4.1).  Gross 
evaluation of FAKwnt neonates at P0-P1.5 revealed no significant difference in external 
appearance from the genetic control littermates.  Indeed, FAKwnt and genetic control 
neonates were similar in size and had normal limb and cranial-facial development (data 
not shown).  However, gross morphology of the cardiac outflow tract of FAKwnt mice 
revealed aberrant septation and branching of the major outflow vessels (Figure 4.1).   
We next performed a histological analysis of FAKwnt and littermate genetic 
control hearts at selected time points from E12.5-P0 to evaluate outflow tract 
development.   We found that 100% of the FAKwnt embryos exhibited PTA, indicating 
that FAK expression in CNC cells is necessary for appropriate septation of the truncus 
arteriosis (Figure 4.1).  Examination of other neural crest derived tissues such as cranial 
bones and thymic lobes revealed no obvious abnormalities, indicating that the initial 
delamination, migration, and proliferation of neural crest was normal.  We next examined 
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SM marker gene expression in the FAKwnt mice to determine whether FAK was 
necessary for SMC differentiation.  Somewhat suprisingly, we found that the FAKwnt 
mice exhibited a thick layer of SM -actin- and SM-22-positive SMC within the walls of 
the un-septated truncus arteriosis (Figure 4.2) and carotid arteries (data not shown).  
Indeed, SM-22 staining appeared particularly intense in the OFT of FAKwnt in 
comparison to similar regions of the genetic controls (arrows, Figure 4.2b).  We 
previously showed that conditional deletion of FAK in nkx2-5-expressing cells (FAKnk) 
resulted in completely penetrant ventricular septal defects accompanied by significant 
outflow tract abnormalities, including PTA.  Since nkx2-5-dervied SMC also contribute 
to formation of the aortic root and septum, we next examined FAKnk mice for defects in 
smooth muscle maturation.  Similar to what we observed in the FAKwnt mice, we found 
that the single vessel arising from FAKnk embryos that exhibited PTA was fully invested 
with SMC, as assessed by robust SM -actin staining (Figure 4.3).  Collectively, these 
studies indicate that FAK is not required for neural crest cell function or the 
differentiation of wnt-1 or nkx2-5 expressing cells to SMC, but is essential for the 
formation of the aorticopulmonary septum during OFT development. 
Aorticopulmonary septation occurs between E11.5 and E12.5 when a wedge of 
CNC-derived SMC extends from the dorsal region of the aortic sac and ultimately fuses 
to the ventrally growing conotruncal septum to partition the aortic sac into distinct aortic 
and pulmonary channels and align the great vessels with the left and right ventricles 
respectively.  While almost nothing is known about the regulation of SMC during this 
morphogenetic process, several fundamental cellular functions including directional 
motility, cell growth and cell differentiation are likely involved.  In order to evaluate the 
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necessity for FAK in these cellular processes, we next established an aortic SMC culture 
from fakflox/flox mice.  As shown in Figure 4.4, incubation of fakflox/flox SMC with Cre 
adenovirus for 72 hr resulted in a significant depletion of FAK protein, while levels of 
FRNK, and the FAK homologue, Pyk2 were not significantly affected.  Importantly, the 
FAK-null SMC maintained a well spread phenotype and exhibited similar organization of 
vinculin-containing focal adhesions and actin filament distribution when compared to 
FAK-containing control SMC (Figure 4.4b).   
We first evaluated the effect of FAK depletion on SMC growth and survival.  We 
found no significant difference in the rate of BrdU incorporation in continuously growing 
fakflox/flox cells treated with LacZ or Cre adenovirus (Figure 4.5A).  We also found 
comparable rates of cell growth under serum-free conditions and in cells stimulated with 
the SMC mitogens PDGF-BB and EGF (Figure 4.5B).  Accordingly, mitogen-stimulated 
ERK activity and cyclin D protein levels were similar in Cre- and LacZ- treated cells 
(Figures 4.5C and 4.5D), indicating that FAK was not required for activation of the major 
mitogenic Ras/ERK signaling pathway in SMC.  Consistent with our findings that 
deletion of FAK did not alter cell growth, we observed no significant difference in cell 
survival as measured by caspase 3/7 activity (Figure 4.5E).  Collectively, these data 
indicate that defective aorticopulmonary septation in the FAKwnt and FAKnk mice is not 
likely due to inhibition of SMC proliferation or aberrant apoptosis.  
We next examined the effect of FAK on SMC motility, another candidate cellular 
response critical for aorticopulmonary septation.  Using a modified Boyden chamber 
assay, we demonstrated that PDGF-stimulated chemotaxis was dramatically reduced in 
FAK-null SMC (Figure 4.6A).  This inhibition was observed across a wide range of FN 
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concentrations, indicating that these effects were not due to altered adhesiveness (data not 
shown).  Interestingly, a similar significant reduction in chemotaxis was observed when a 
modest level of serum (1%) was used as a chemoattractant.  However, this effect could be 
overcome by the strong chemotaxic stimulus induced by higher concentrations of serum 
(10%) indicating that impaired chemotaxis was not due to a global structural deficiency 
in the FAK-null SMC (Figure 4.6B). The marked decrease in PDGF-BB-stimulated 
chemotaxis observed in the FAK-null SMC is likely due to defective recruitment of 
factors to focal adhesion complexes that are required to maintain stable lamellipodial 
projections (LEM and JMT manuscript in preparation).   Since PDGF is known to be 
highly expressed in the conal truncus in this critical developmental window, and has been 
implicated in guiding cells during aorticopulmonary septal formation, it is possible that 
the cause of the PTA in FAKwnt and FAKnk mice was due to a defective response of SMC 
to this chemokine (150, 155). 
We observed a qualitative increase in SMC-marker gene expression in the OFT of 
the FAKwnt mice.  Since premature SMC differentiation may affect whether a SMC can 
populate the aortic sac, we next strove to determine whether SMC marker genes might be 
elevated in FAK-null SMC cultures.  We first examined the protein levels of SRF-target 
genes in LacZ- and Cre-treated SMC maintained in 10% serum.  As shown in Figure 
4.7A, we observed a striking increase in expression of the canonical SM marker gene, 
SM-MHC in FAK-null SMC.  Consistent with this observation, another SRF-target gene 
vinculin was more highly expressed in FAK-null SMC (156), while expression of the 
paxillin (a non-SRF dependent focal adhesion protein) was similar between FAK-null 
and control SMC (Figure 4.7A).  We next asked if TGF--induced SM marker gene 
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expression was altered in FAK-null SMC.  As shown in Figure 4.7B, while basal levels 
of SM -actin were similar in serum-starved Cre and LacZ-treated SMC, TGF- induced 
a more marked up-regulation of SM -actin protein levels in Cre-treated compared to 
LacZ treated SMC.  To test whether this effect was due to enhanced SMC-specific 
transcription, we examined the responsiveness of an SM-22 promoter/luciferase reporter 
in these cells.  As shown in Figure 4.7C, SM-22 activity in control SMC was induced 2-
fold by TGF-, but by 10-fold in FAK-null cells (top panel).  A similar enhancement in 
TGF- induced expression of the SM -actin and SM-MHC promoters was also observed 
in FAK-null SMC (Figure 4.7C middle, bottom panels).  Importantly, ectopic expression 
of wild type FAK reversed the enhanced expression of SM -actin induced by TGF- 
(Figure 4.7D).  Taken together, our findings provide evidence that FAK depletion 
attenuates PDGF-stimulated chemotaxis, but promotes TGF--stimulated SMC 
maturation.    
We next strove to determine the precise mechanisms by which FAK inactivation 
enhances SMC differentiation, since this finding could have important implications on 
the regulation of SMC phenotype during development and disease.  The canonical 
pathway by which TGF- stimulates SMC gene transcription is through activation of 
Smad2/3 transcription factors.  TGF--mediated phosphorylation and subsequent nuclear 
localization of Smad2 and Smad3 can stimulate SMC-specific transcription (117, 118, 
148), and Smad binding elements (SBE) have been identified in a number of SMC-
specific promoters. However, we found that FAK deletion did not significantly enhance 
Smad2/3 activity.  Indeed, a consistent lag in Smad2 and Smad3 phosphorylation was 
apparent in FAK-null SMC, following TGF- treatment indicating that the initial phase 
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of SMAD signaling may actually be FAK-dependent (Figure 4.8A).  Further, TGF- 
stimulated similar activation of a multimerized Smad binding element promoter/reporter 
construct (6xSBE/Luc) in Cre- and LacZ-treated fakflox/flox SMC, indicating that FAK 
likely acts to enhance TGF--stimulated SMC gene expression by a Smad-independent 
mechanism (Figure 4.8B).    
It is becoming clear that RhoA activation is an important determinant of SMC 
differentiation marker gene expression.  Indeed the strong RhoA agonist, sphingosine-1-
phosphate (S1P), has been shown to induce SMC differentiation through a mechanism 
involving RhoA dependent translocation of the potent SRF co-factors MRTF-A and B 
(128, 157).  Interestingly, previous studies have shown that FAK-null fibroblasts exhibit 
enhanced basal RhoA activity, indicating the possibility that this pathway might be 
involved in promoting SMC maturation in FAK-null SMC (158).  However, we found 
that basal and S1P-stimulated RhoA activity were comparable in LacZ- and Cre-treated 
SMC (Figure 4.9A) and that TGF- treatment did not lead to detectible levels of RhoA 
activation at select time points examined from 2 min-4 hrs in either LacZ- (Figure 4.9B) 
or Cre-treated cells (data not shown).  In agreement with our biochemical assays, we did 
not observe enhanced nuclear localization of either MRTF-A or MRTF-B in vehicle-, 
S1P-, or TGF--treated FAK-null SMC in comparison to similarly treated FAK 
containing SMC (data not shown).   Collectively, these data argue against enhanced 
RhoA activation as a major mechanism involved in the modulation of TGF- induced 
SM marker gene expression in FAK-null SMC.   
Another downstream signaling molecule implicated in TGF- stimulated gene 
expression is the MAPK family member p38.  p38 is known to be a critical player in 
 96
skeletal muscle myotube formation and has been recently implicated in promoting 
cardiac and smooth muscle differentiation and in the conversion of fibroblasts to SM -
actin expressing myofibroblasts (159-161).  We found that the p38/ subunit inhibitor, 
SB203580 (10 M) dramatically reduced TGF- stimulated SM marker gene promoter-
reporter expression in 10T1/2 SM precursor cells (Figure 4.10A).  This effect was not due 
to toxicity, as parallel experiments revealed that SB203580 treatment did not significantly 
affect PDGF-stimulated SMC chemotaxis (data not shown).  We next evaluated the levels 
of phosphorylated (active) p38 in LacZ- and Cre-treated cells following TGF- treatment.  
As shown in Figure 4.10B, the time course of p38 activation was prolonged and the peak 
p38 activity was more pronounced in FAK-null SMC in comparison to FAK-containing 
SMC.  As expected, treatment with SB203580 reversed the elevated SM gene expression 
observed in FAK-null SMC (data not shown).  Thus, enhanced p38 activity may account, 
at least in part, for the observed increase in SM marker gene expression observed in FAK 
null SMC.  
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DISCUSSION 
 
In the current study we demonstrated that conditional deletion of FAK in wnt-1- 
or nkx2-5-expressing cells led to PTA that was incompatible with post-natal life.  Given 
that aorticopulmonary septation involves the precise spatial and temporal coordination of 
several SMC processes including migration, proliferation, differentiation, and apoptosis, 
these studies suggest that FAK plays a critical role in SMC development.  Indeed, our 
studies in FAK-null aortic SMC cultures revealed a dual function for FAK in regulating 
SMC phenotype. FAK inactivation attenuated serum- and PDGF-BB-dependent 
chemotaxis, and also promoted serum- and TGF--stimulated SMC differentiation 
marker gene expression. To our knowledge these studies are the first to define a cell 
autonomous role for FAK in the developing OFT and provide interesting new insights 
into the mechanisms underlying some of the most common congenital defects in humans 
including Tetralogy of Fallot and the DiGeorge Syndrome.   
    Interestingly, PTA has been associated with a block in SMC differentiation 
within the truncus of mice harboring null mutations in the BMP receptor, Alk-2 and 
MRTF-B as well as those with CNC-targeted expression of a dominant negative Notch 
variant (15-17, 162).  However, similar to our studies, CNC-targeted ablation of 
TGFR2, PDGFR/, and Gata 6 each lead to fully penetrant PTA without a noticeable 
reduction in SMC number or SMC maturation (150, 151, 163).   In fact, Choudhary, et al. 
noted that at a stage prior to aorticopulmonary septal formation, the cells at the distal end 
of the aortic sac (where aorticopulmonary wedge formation is initiated) prematurely 
expresses very high levels of SM marker genes in wnt-1Cre/tgfr2 mutants (151). Taken 
together, these finding may suggest that precise regulation of SMC phenotype within the 
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walls of the aortic sac is necessary for subsequent formation of the aorticopulmonary 
septum.  Since PDGF (164), GATA6 (165), and now FAK have each been implicated in 
the maintaining SMC in an immature, synthetic state, it is tempting to speculate that 
precocious SMC maturation may occur when these molecules are inactivated.  However, 
it is also clear from our studies and others that both PDGF and FAK are also necessary 
for directional motility, indicating that lack of these molecules could impede motility of 
either neural crest or secondary heart-field derived mesencymal cells into the conotruncal 
region.  Thus, although we do not yet know the precise causative factor(s) for PTA, it is 
possible that both precocious SMC maturation and defective motility lead to the aberrant 
morphogenetic patterning of the cardiac OFT observed in the FAKnk and FAKwnt mice. 
Our lab recently showed that FAK activity is regulated in a unique fashion in 
SMC by the selective expression of a separate protein comprising the carboxyterminus of 
FAK, termed FRNK (FAK Related Non Kinase) that acts as a dominant-interfering 
mutant for FAK (122). FRNK expression is very high in large arterioles and is greatly 
increased after birth and from two to three weeks following vessel injury, times when 
SMC are transitioning from a synthetic to contractile phenotype (122).  Although FRNK 
null mice exhibited no overt phenotype (166), FAK activity was enhanced in FRNK-/- 
SMC tissues while SMC differentiation marker gene expression was reduced during post-
natal vessel growth and following vascular injury (unpublished observations, RLS and 
JMT). Interestingly, FAK-null mouse embryonic fibroblasts exhibit a myofibroblast 
appearance with increased SM -actin expression further supporting a role for FAK 
activation in the regulation of SMC phenotype (133). 
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In addition, recent studies also suggest that FAK promotes striated muscle cell 
differentiation.  Clemente, et al. showed that the induction of differentiation of C2C12 
cells into myotubes is accompanied by a transient inhibition of FAK activity from 0-2 hrs 
followed by later increase in FAK activity that lasted up to 5 days.  Interestingly, ectopic 
expression of a FAKY397F variant that reduced FAK activity in C2C12 cells lead to 
enhanced skeletal muscle marker gene expression, although FAK inactivation ultimately 
blocked myotube formation (134). Stable expression of FRNK in embryonic stem (ES) 
cells was shown to induce cardiac -myosin heavy chain and sarcomeric myosin 
expression (135).  Previous studies from FAK-null ES cells revealed that the absence of 
FAK did not preclude hematopoetic differentiation or differentiation of cells into all three 
germ layers (167), but no mention was made of the relative contributions of FAK-null 
cells to mesenchymal compared to non-mesenchymal lineages.  Since numerous reports 
suggest that FAK activity is required for osteoblast differentiation it is possible that 
limiting FAK activity might enhance SRF-dependent muscle cell differentiation at the 
expense of cartilaginous cell differentiation(168).  Further careful examination of the 
multi-lineage potential of FAK-/- ES cells using a combination of in vitro and chimeric 
approaches should aid in determining which cell types are restricted and which are 
promoted by FAK activation.  
The well spread morphology of our FAK-null SMC differs from previously 
described embryonic FAK-null fibroblasts which were more rounded, possibly due to 
enhanced RhoA activation (169, 170). It is important to emphasize, however, that FAK-
null fibroblasts expressed high levels of Pyk2 and that compensatory pathways are 
frequently up-regulated in cells isolated from conventional knock-out mice.  Importantly, 
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our results are in excellent agreement with previous work from Tilghman, et al. who 
demonstrated that repression of FAK expression in fakflox/flox fibroblasts by adenoviral 
mediated CRE delivery or siRNA did not result in significant morphological changes 
(121). We did however observe a consistent increase in vinculin protein levels in the 
absence of FAK, supporting our hypothesis that SRF-dependent gene transcription is 
elevated in FAK-null cells (171). 
Of the several potential mechanisms by which FAK activity could modulate TGF-
 dependent SMC differentiation, our data support a role for p38. Although FAK and 
TGF- have been shown to affect RhoA activity (160, 169, 170), neither of these signals 
altered this pathway in our SMC culture model. FAK activation is also required for full 
ERK activity in some models and it has been previously shown that ERK-dependent 
activation of the SRF co-factor, Elk-1, negatively regulates SMC marker gene expression 
by competitively interfering with the myocardin binding to SRF (172-175). While FAK 
deletion in SMC attenuated PDGF-stimulated migration, we did not observe any 
significant difference in either the kinetics or amplitude of PDGF- or EGF-stimulated 
ERK activation in FAK-null SMC.  In contrast, we did observe a significant enhancement 
of p38 activity in FAK-null SMC which was required for enhanced SMC differentiation 
marker gene expression.  Importantly, p38 activity has been shown to promote smooth, 
cardiac, and skeletal muscle differentiation as well as SM -actin expression in 
fibroblasts (159-161). p38 activity is not required for skeletal muscle specification, but 
inhibition of p38 activity markedly attenuated expression of a subset of MyoD target 
genes classified as late muscle structural genes (159).  This effect may be due to impaired 
p38-dependent recruitment of the SWI-SNF chromatin remodeling complex to the 
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promoters of these target genes (176).  In addition, p38 has been shown to directly 
phosphorylate the SRF-cofactors, MEF2A, C, D and GATA-4 at residues located within 
the transactivation domain of each of these proteins and this phosphorylation is necessary 
for their full transcriptional activities (159).   Interestingly, SRF is itself a target for 
phosphorylation by MK2 (a downstream effector of p38) and activation of MK2 is 
necessary for TGF- stimulated myofibroblast differentiation (177, 178).  Whether p38 
functions in a similar fashion to regulate SRF or additional SRF-cofactors involved in 
SMC differentiation is not yet known.   
FAK is a multifunctional protein that associates with a number of adapter 
molecules through well defined protein interaction sites, and it is also possible that 
specific FAK binding partners could be involved in modulating the SMC phenotype.  
Interestingly, we recently reported that the FAK-interacting protein leupaxin shuttles 
from focal adhesions to the nucleus, where it acts as an SRF co-factor to enhance SM 
marker gene expression (179). Furthermore, we showed that expression of a 
constitutively active FAK variant leads to sequestration of leupaxin within focal 
adhesions and reduces leupaxin-dependent gene transcription (179).  Conversely 
(although a suitable leupaxin antibody is not available to detect endogenous leupaxin in 
our primary mouse SMC cultures) we have noted that ectopically expressed GFP-
leupaxin exhibits a more nuclear restricted localization in FAK-null SMC in comparison 
to FAK containing SMC (unpublished observations).  Studies to determine the relative 
contributions of (or relationship between) leupaxin and p38 in regulating SMC 
phenotypes in FAK null SMC are ongoing in our laboratory. 
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In conclusion, our studies indicate that FAK plays a direct role in regulating the 
formation of the aorticopulmonary septum during outflow tract development. We 
postulate that direct modulation of FAK activity (or the intrinsic shifting of FAK/FRNK 
expression) likely mediates a balance between SMC migratory and contractile capacities 
necessary for proper morphogenesis of this structure.  With respect to adult onset disease, 
is clear that dynamic SMC phenotypic switching is a key factor in the development and 
progression of restenotic lesions.  Since the data from our current and previous studies 
indicate that FAK activity promotes SMC migration and down regulation of 
differentiation marker gene expression, it will be of future interest to determine whether 
SMC-restricted FAK inactivation (or FRNK expression) in large vessels at later 
timepoints might control neo-intimal formation by preventing SMC phenotypic 
modulation. 
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 Table 4.1. Variable offspring from fak+/- x fak+/fl wnt-1+/Cre intercross. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expected percentage: 12.5% for each genotype; P0, n = 43; P14, n = 13. 
 P0          P14 
 Percentage  Percentage  fak Copy Number 
fak+/+ wnt-1+/+ 19   15   2 
fak+/+ wnt-1+/Cre 9   8   2 
fakfl/+ wnt-1+/+ 23   8   2 
fakfl/+ wnt-1+/Cre 16   15   1 
fak+/- wnt-1+/+ 2   31   1 
fak+/- wnt-1+/Cre 5   15   1 
fakfl/- wnt-1+/+ 7   8   1 
fakfl/- wnt-1+/Cre 19  0  0 
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Figure 4.1.  Deletion of fak from the cardiac neural crest causes septation defects in the 
truncus arteriosus.   A.  Gross morphology of the cardiac outflow tract in P0 genetic control 
(left) and two examples of outflow defects in FAKwnt mice (right).  Lines are drawn to indicate 
morphology of the great vessels (white, aorta; blue, pulmonary artery). Schematics below 
illustrate the nature of the observed defects.  RA-right atrium, LA-left atrium.  B.  Transverse 
sections through the cardiac outflow tract of embryonic day (E) 13, 14 or P0 genetic control 
(left) or FAKwnt (right) mice stained with H&E.  Data are representative of at least 5 mice.  
PT-pulmonary trunk, Ao-Aorta, PTA-persistent truncus arteriosis. 
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C. 
Figure 4.2. PTA is not a result of impaired SMC investment in OFT of FAKwnt embryos.  
Immunohistochemistry for SM -actin (A) or SM-22 (B) reveals thick layer of differentiated 
SMC in both genetic control (left) and FAKwnt (right) mice from E13 to P0.  Boxes in Panel B 
are shown at higher magnification in Panel C.  C. High power magnification showing cross 
section through vascular wall of the aorta and pulmonary artery of genetic control embryo and 
the truncus arteriosis of FAKwnt embryo at E14.  SM2-22 immunohistochemistry demonstrates 
a marked increase in neural creast-derived SMC in FAKwnt OFT.  Data are representative of at 
least 5 mice.  PT-pulmonary trunk, Ao-Aorta, PTA-persistent truncus arteriosis. 
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Figure 4.3. Conditional deletion of fak in Nkx2-5-expressing cells leads to PTA 
accompanied by pronounced SMC investment within the OFT.  Transverse sections 
through the cardiac outflow tract of P0 genetic control (top) or FAKnk mice (bottom).  Sections 
were stained with H&E (left) or processed for immunohistochemistry using an anti-SM -
actin antibody (right).  Approximately 15% of FAKnk mice presented with PTA.  Data are 
representative of at least 5 mice.  DAo-dorsal aorta, PT-pulmonary trunk, OFT-outflow tract, 
DA-ductus arteriosus, Ao-aorta, A-atrium, E-esophogus. 
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Figure 4.4. Characterization of FAK-null SMCs.  A.  fakflox/flox SMC maintained in 10% 
serum were infected with either LacZ or Cre adenovirus for 72 hrs, cells were lysed, and 
Western blotting was performed using either anti-C-terminal FAK (that recognizes both FAK 
and FRNK), or anti-Pyk2 specific antibodies.  B. fakflox/flox SMC maintained in 10% serum 
were infected with either LacZ or Cre adenovirus for 72 hrs prior to fixation. Cells were 
permeablized, blocked, and stained with phalloidin and either anti-FAK (N-terminal specific) 
or anti-vinculin specific antibodies and processed as described in the Material and Methods 
section.  Data are representative of at least three experiments. 
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Figure 4.5.  FAK depletion does not affect SMC growth or growth factor-stimulated 
ERK activation.  fakflox/flox  SMC were infected with either Cre or LacZ adenovirus for 72 hrs.  
A.  Cells maintained in serum were assessed for BrdU incorporation as described in Materials 
and Methods B.  Cells were serum starved for 24 hrs prior to treatment with either PDGF-BB 
(20 ng/ml) or EGF (100 ng/ml) for 48 hrs prior to determining WST-1 activity as described in 
the Materials and Methods section.  C. Cre or LacZ infected  fakflox/flox  SMC were serum 
starved for 24 hrs prior to treatment with either PDGF-BB (20 ng/ml) or EGF (100 ng/ml) for 
the times indicated.  Cells were lysed, electrophoresed and Western blotting was performed 
with anti-FAK, anti-active pERK1/2 and anti-ERK antibodies.  D. fakflox/flox  SMC were 
infected with either Cre or LacZ adenovirus for 72 hrs.  Cells were then serum starved for 4 
hrs prior to treatment with either 10% serum (SM) or PDGF-BB (20 ng/ml) for 24 hrs.  Cells 
were lysed, electrophoresed, and Western blotting was performed with anti-FAK, anti-Cyclin 
D1 and anti-ERK antibodies.  E. Caspase 3/7 activity was measured in serum starved Cre or 
LacZ infected fakflox/flox  SMC.  Data are representative of at least three individual experiments. 
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Figure 4.6.  FAK depletion attenuates serum- and PDGF-stimulated chemotaxis.  Cre- or 
LacZ-infected fakflox/flox SMC (treated as described above) were plated on fibronectin-coated 
inserts (3 g/ml; Bio-Coat) in serum-free media using either PDGF-BB (20 ng/ml; panel A) or 
serum (1 or 10%, panel B) as the chemoattractant which was applied to the bottom chamber as 
described in the Methods section.  After a 7 hr incubation cells were stained and counted in 
four fields.  Data represent mean +/- SE for 4 separate experiments. 
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Figure 4.7.  FAK depletion enhances SM gene expression.  A. fakflox/flox SMC were infected 
with either Cre or LacZ adenovirus for 72 hours.  Cells maintained in 10% serum were lysed 
and Western blotting was performed using either anti-paxillin, anti-vinculin, anti-SM-MHC, 
or anti-ERK specific antibodies. B. fakflox/flox SMC were infected as mentioned above.  Cells 
were serum starved for 24 hrs prior to TGF- treatment for times indicated.  Western blotting 
was performed with anti-SM -actin and anti-Pyk2 (loading control) antibodies.  C. fakflox/flox 
SMC were transfected with SM-22, SM -actin, or SM-MHC luciferase reporter constructs.  6 
hrs post transfection cells were infected with Cre or LacZ adenoviruses.  24 hrs following 
infection, cells were serum starved for 24 hrs prior to treatment with TGF- (1ng/ml) 
overnight.  Cells were lysed and luciferase activity was measured.  D. fakflox/flox  SMC were co-
transfected with the SM -actin-luciferase promoter and either empty Flag vector or Flag-
FAK.  6 hrs following transfection cells were infected with either Cre or LacZ adenovirus.  24 
hrs following infection, cells were rinsed and serum starved for 24 hrs and then treated with 
1ng/ml TGF- overnight.   Cells were lysed and luciferase activity was measured.  Data is 
representative of 3 individual experiments. 
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Figure 4.8. FAK depletion does not enhance TGF- stimulated Smad activation or 
transactivating capacity.  A. fakflox/flox SMC were infected with LacZ or Cre adenovirus as 
mentioned above.  Cells were serum starved for 24 hrs prior to TGF- treatment for times 
indicated.  Western blotting was performed with anti-phospho-Smad2, anti-phospho-Smad3, 
anti-FAK and anti-ERK antibodies.  B. fakflox/flox SMC were infected with LacZ or Cre 
adenovirus as mentioned above.  Two days following infection, cells were transfected with 6x-
SBE-luciferase.  After 24 hrs, cells were rinsed and serum starved 8 hours prior to treatment 
with TGF- (1ng/mL).  24 hrs later, cells were lysed and luciferase activity was measured.  
All data represent at least 3 separate experiments.  
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Figure 4.9.   FAK depletion does not affect RhoA activity.  A. fakflox/flox SMC were infected 
with LacZ or Cre adenovirus as mentioned above.  Cells were serum starved for 24 hrs prior to 
S1P (panel A) or TGF- (panel B) treatment for times indicated.  Cell lysates were incubated 
with GST-rhotekin beads as described in the Materials and Methods section.  Active RhoA 
(present in the precipitations) and total RhoA were detected by Western analysis.  
Densitometric analysis of three separate experiments revealed no significant difference in 
basal or S1P-stimulated RhoA activation in Cre- compared to LacZ-infected cells.  All data 
represent at least 3 separate experiments. 
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Figure 4.10.  p38 activity is necessary for TGF- enhanced SM gene transcription and is 
enhanced in the absence of FAK.  A. 10T1/2 cells were transfected with SM-22 luciferase.  
24 hrs later, cells were starved in DMEM containing 0.2% FBS.  The next day, cells were 
pretreated with SB compound (10 M) for 1 hour, and then treated with TGF- for 24 hours.  
Cells were subsequently lysed and assayed for luciferase activity.  B. fakflox/flox SMC were 
infected with LacZ or Cre adenovirus as mentioned above.  Cells were serum starved for 24 
hrs prior and again for 2 hrs prior to TGF- treatment for times indicated.  Western blotting 
was performed with anti-FAK, anti-phospho-p38, and anti--tubulin antibodies.   
 
 
CHAPTER V 
 
DISCUSSION 
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Within this dissertation, I have presented multiple findings that further delineate a 
role for focal adhesion kinase and its family member, FRNK, in smooth muscle cell 
growth and differentiation.  Prior to these studies, little was known about how FRNK 
expression was regulated in smooth muscle cells, or what function FRNK had in vivo.  
Focal adhesion kinase, however, is a well studied protein and its function in a variety of 
cell types has been previously determined.  Since germline deletion of FAK results in 
embryonic lethality due to general mesodermal defects, it has been thought that FAK 
plays a significant role in formation of the vasculature and in guidance of smooth muscle 
cells.  Here, by using a variety of integrative in vitro and in vivo approaches, we have 
shown that both FAK and FRNK are critical for proper smooth muscle cell function. 
 
FAK: A NEW ROLE IN SMOOTH MUSCLE CELLS 
 
 As described previously, others have demonstrated that FAK is essential for 
proper development during embryogenesis.  FAK has also been shown to upregulate 
proliferation by mediating outside-in signaling from integrins, G-protein coupled 
receptors, and growth factors.  Here we have shown that FAK is required in cardiac 
neural crest-derived cells for proper septation of the cardiac outflow tract and provided 
additional evidence that supports an emerging role for FAK as a regulator of 
differentiation.  As described in Chapter IV, FAK has recently been implicated as a 
regulator of differentiation in skeletal and cardiac muscle cells (134, 135). 
 In addition to playing an important role in formation of the cardiac outflow tract 
during embryogenesis, we also expect that FAK is an important regulator of proliferation 
and differentiation in smooth muscle cells derived from other origins.  Moreover, we 
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hypothesize that FAK activity is important for smooth muscle cell growth and neointima 
formation following vascular injury.  However, it has been difficult to conditionally 
delete FAK in smooth muscle derived from distinct origins because of the lack of 
effective Cre-expressing mouse lines.  Future studies include looking at the role of FAK 
in maturation of other vessels at early postnatal timepoints when smooth muscle cells are 
maturing and thickening the vascular wall.  It is also a goal of our laboratory to determine 
a role for FAK following vascular injury by carotid artery ligation.  These studies will 
provide further insight into FAK’s role as a modulator of smooth muscle cell phenotype. 
 
FRNK AS A REGULATOR OF SMOOTH MUSCLE CELL DIFFERENTIATION 
 
 This work provides evidence that FRNK regulates differentiation of smooth 
muscle cells.  FRNK is frequently used as a tool by investigators to attenuate FAK 
activity and FAK-dependent downstream mitogenic and migratory pathways.  Likewise, 
our laboratory has also demonstrated that FRNK can inhibit PDGF-stimulated growth 
and migration in vascular smooth muscle cells (93).  We originally hypothesized that in 
the absence of FRNK, smooth muscle cells would lack a mechanism to negatively 
regulate FAK activity, and therefore would be hyperplastic.  Although proliferation did 
increase in smooth muscle organs in developing FRNK-/- mice, we did not see any effect 
on vessel wall diameter in adult animals.  Instead, our in vitro and in vivo evidence have 
shown a more significant role for FRNK in regulating smooth muscle cell differentiation.  
In particular, we were able to show that overexpression of FRNK results in higher 
activity of smooth muscle gene promoters.  Using our in vivo model, we also made the 
interesting discovery that in the absence of FRNK, there are lower levels of smooth 
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muscle gene expression both during development and following vascular injury.  This 
evidence suggests that methods to enhance FRNK expression might provide means to 
control unwanted proliferation. 
 Herein, we show that TGF-upregulates FRNK expression and that expression of 
FRNK can enhance the response of smooth muscle cells to treatment with TGF-.  At 
this point it unclear how FRNK is able to enhance this response, but there are potential 
mechanisms currently under investigation.  Recently, our laboratory identified leupaxin 
as a mediator of smooth muscle cell differentiation that binds FAK (179).  It is possible 
that by forming inhibitory heterodimers with FAK, FRNK is able to allow increased 
localization of leupaxin to the nucleus to stimulate smooth muscle gene expression.  It is 
also possible that FRNK could mediate p38 MAPK signaling, which can act downstream 
of TGF- and promote differentiation. 
 
REGULATION OF FRNK EXPRESSION 
 
 Previous studies have indicated that FRNK is specifically expressed in smooth 
muscle-containing tissues (93, 96).  Hayasaka et al. recently generated a mouse model in 
which LacZ expression is under control of the 6kb FRNK promoter (96).  This region 
directed vascular specific expression of LacZ in arteries and arterioles.  However, this 
clearly does not contain all of the elements that control FRNK expression.  Notably, this 
promoter does not direct expression in visceral smooth muscle, while our in situ analysis 
reveals that FRNK is highly expressed not only in the lung vasculature, but in airway 
smooth muscle and bladder.  In addition, our work here indicates that there is a low level 
of FRNK expression in the developing coronary vasculature, but the LacZ promoter-
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reporter mouse demonstrates no expression seven days following birth in these vessels.  
Interestingly, we have recently been able to detect transient expression of FRNK days 
after birth in the mouse.  These findings are important to consider when determining what 
factors regulate FRNK expression.  Future studies with transgenic animal models are 
needed to elucidate the exact expression pattern of FRNK.  Present studies of FRNK 
expression have only included a portion of the entire non-coding sequence that directs 
FRNK expression.  It is likely that regions exist outside of the well-studied 6kb region 
that regulates expression of FRNK in coronary vascular or lung airway smooth muscle.  
Therefore, mouse models that utilize these regions may better illustrate the tissues where 
FRNK is expressed.  It would be possible to generate transgenic lines using portions of 
the FRNK promoter cloned from BACs to examine promoter regions out of the 6kb 
construct.  A caveat of the current promoter-reporter model is that LacZ expression can 
only be observed in those tissues that activate the promoter at the examined 
developmental time.  An alternate model would use a region of the FRNK promoter to 
drive expression of Cre recombinase.  By crossing this mouse with a Rosa26 reporter 
mouse, any cell that even transiently expressed FRNK would be marked by LacZ 
throughout development. 
 As discussed previously, the majority of smooth muscle-specific gene expression 
is regulated by serum response factor binding to CArG-elements within the promoters of 
these genes.  This work demonstrates that FRNK is not regulated by SRF, or by its potent 
co-activators, myocardin and MRTF-A.  However, as discussed in the Introduction, 
several other smooth muscle specific genes are also regulated in a CArG-independent 
fashion.  In the study of HRCBP, the authors identified highly conserved elements within 
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the promoter that were necessary for HRCBP expression and under the control of the 
transcriptional enhancer Mef2C (103).  In this study, we chose to undertake a similar 
approach and assume that the most important regions of the FRNK promoter are likely 
those regions highly conserved across species.  Indeed, two regions over 75% conserved 
across rat, mouse, and human were identified and shown to be necessary and sufficient 
for smooth muscle specific expression in cultured cells.  Although additional studies are 
required to determine what factors regulate these conserved regions, we have made much 
progress using novel screening methods to identify enhancers of the FRNK promoter. 
 At this point, it is interesting to point out the innovative methods now employed 
to identify functional regions of non-coding gene elements.  It is most important to 
determine what elements regulate gene expression in vivo.  Investigators are currently 
moving towards initially screening for important elements by generating sets of 
promoter-reporter mice that each contains a portion of a non-coding region of interest.  
Creemers, et al. were able to identify a short region of the myocardin promoter that 
directed expression of LacZ during embryogenesis (180).  After locating this region, they 
were able to identify specific activators of the myocardin promoter using the screen 
described in Chapter II and by Chang, et al. (109, 180).  As the generation of transient 
transgenic animals becomes more cost effective for investigators, this will be a direct way 
to find significant non-coding regions responsible for regulation of gene expression. 
  
CLINICAL IMPLICATIONS 
 
  Although the majority of this work utilized murine models, the goal of each study 
is always to contribute to medical knowledge that will eventually be used in a clinical 
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setting.  Our studies are relevant to two human disorders, congenital heart defects 
associated with aberrant outflow tract development and restenosis post-stent 
implantation.   
 Proper development of the heart and outflow tract is critical for successful human 
development.  DiGeorge syndrome is an example of a congenital heart defect generally 
exhibiting persistent truncus arteriosis (PTA), as seen here in FAK-deficient mice.  In 
addition to PTA, DiGeorge syndrome is also characterized by an interrupted aortic arch, 
malformation of the thymus and/or parathyroid glands, craniofacial dysmorphology, and 
psychological disorders (181).  This overall defect in neural crest development has been 
linked to a microdeletion on chromosome 22q11.  Studies have indicated that the 
microdeletion is the gene Tbx1, a known regulator of cardiac development.  However, 
not all DiGeorge patients have a deletion of Tbx1, nor do they all share the same severity 
of symptoms (181).  It is likely that the variety of DiGeorge symptoms is modified by 
other genes.  Since this work implicates FAK deletion in contributing to PTA, it is 
possible that FAK may be a candidate modifier gene in this congenital defect. 
 The incidence of hypertension and atherosclerosis in the United States population 
is severe.  Smooth muscle cell growth contributes to the development of these diseases 
that can each lead to heart attack and stroke.  Since this work has made clear the 
contribution of FAK and FRNK to smooth muscle cell proliferation, this could be 
manipulated to attenuate medial thickening during hypertension and invasion and growth 
of atherosclerotic plaques.  In addition, modulation of TGF- has been linked with 
development of hypertension (182, 183).   When TGF- is allowed to accumulate, its 
presence causes premature differentiation and a constricted vessel lumen.  In this case, it 
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may possible that TGF- stimulates the release of FRNK and in turn is better able to 
activate smooth muscle specific gene expression. 
As described in Chapter I, restenosis following surgery to clear blocked 
atherosclerotic arteries is significant medical condition.  Since FAK is known to be 
activated following vascular injury, it is important to understand the downstream 
pathways that lead to smooth muscle cell growth and migration.  Because FRNK is 
known to negatively regulate FAK activity, it is possible that FRNK could be potentially 
used as a therapeutic in vascular stents.  Current stent technology is utilizing other agents 
that are able to reduce the amount of cellular proliferation within the vessel following 
injury.  If transcriptional activators of the FRNK promoter are identified, it is possible 
that a treatment could be formulated to increase their activity to induce FRNK expression 
in the vessel. 
 
A MODEL FOR FAK AND FRNK IN SMOOTH MUSCLE CELLS 
 
 The studies presented here in this dissertation have elucidated new roles for FAK 
and its family member FRNK in vascular smooth muscle cells.  Previously, FAK was 
known as an integrator of proliferative signals from a variety of outside sources.  FRNK 
also acts as a dominant negative and can attenuate PDGF-stimulated proliferation and 
migration in smooth muscle cells (93).   
 FAK has a well-described role as a mediator of signaling from integrins, growth 
factor receptors, and G-protein coupled receptors.  Agonists such as fibronectin, PDGF, 
and angiotnsin II all activate FAK by phosphorylation of Y397.  This signaling is 
particularly important during development, when smooth muscle cells or pericytes must 
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migrate towards sites of vessel formation and then proliferate to form a medial layer 
around the vessel.  As the vessel matures and smooth muscle begins to differentiate into 
contractile cells, the complement of growth factors an matrix around the vessel begins to 
change.  The microenvironment becomes rich with TGF- and herein we demonstrate 
that this factor upregulates FRNK expression in vitro.  FRNK expression is also increased 
in vivo during development at times that correspond to expression of pro-differention 
markers.  It is likely that FRNK is expressed at these times to attenuate FAK-depdendent 
proliferation and migration and to enhance expression of smooth muscle genes. 
 The expression of FRNK following vascular injury also lends support to this 
model.  As discussed previously, smooth muscle cells retain the ability to switch between 
contractile and proliferative phenotypes.  Immediately following vascular injury, pro-
proliferative agonists such as PDGF are released, resulting in smooth muscle cell growth.  
In response, TGF- is released within the vessel and is likely a major contributor to the 
increase of FRNK expression.  As smooth muscle cells exhibit pathological growth, 
FRNK is then expressed to negatively regulate FAK activity and promote the re-
expression of smooth muscle genes (see Figure 5.1). 
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Figure 5.1. Model for FAK/FRNK signaling in smooth muscle cells.  In the developing 
vasculature, SMC are embedded in an environment rich in fibronectin and PDGF.  These cells are 
predicted to have high levels of FAK and Rac activity, and thus be highly motile.  As the vessels 
mature TGF-b is induced and FRNK expression is increased.  This leads to FAK inhibition and 
translocation of LIM factors such as leupaxin into the nucleus where they can promote 
differentiation.  In the adult vasculature high levels of collagen are produced and the cells are 
quiescent.  However upon injury, fibronectin is re-expressed and PDGF secretion is increased.  
FAK is reactivated and LIM proteins are suggested and the cells revert to a de-differentiated 
motile phenotype. 
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Figure 5.2.  Model for TGF- signaling with FAK and FRNK.  TGF- signaling through 
Smad proteins and other element can stimulate stranscription of SM genes, such as SM22 and 
smooth muscle -actin (SMA).  However, our work indicates that TGF- upregulates FRNK 
expression in a Smad-independent fashion.  FRNK is also able to upregulate expression of SM 
genes and concurrently block FAK-dependent integrin signaling that increases expression of 
proliferative genes.  This model suggests that p38, an alternative downstream signaling 
pathway for TGF-, may be more highly stimulated in the presence of FRNK. 
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